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Abstract: BACKGROUND The European Society of Cardiology recommends a 0/1-hour algorithm for
rapid rule-out and rule-in of non-ST-segment elevation myocardial infarction using high-sensitivity cardiac
troponin (hs-cTn) concentrations irrespective of renal function. Because patients with renal dysfunction
(RD) frequently present with increased hs-cTn concentrations even in the absence of non-ST-segment
elevation myocardial infarction, concern has been raised regarding the performance of the 0/1-hour al-
gorithm in RD. METHODS In a prospective multicenter diagnostic study enrolling unselected patients
presenting with suspected non-ST-segment elevation myocardial infarction to the emergency department,
we assessed the diagnostic performance of the European Society of Cardiology 0/1-hour algorithm us-
ing hs-cTnT and hs-cTnI in patients with RD, defined as an estimated glomerular filtration rate <60
mL/min/1.73 m2, and compared it to patients with normal renal function. The final diagnosis was
centrally adjudicated by 2 independent cardiologists using all available information, including cardiac
imaging. Safety was quantified as sensitivity in the rule-out zone, accuracy as the specificity in the rule-
in zone, and efficacy as the proportion of the overall cohort assigned to either rule-out or rule-in based on
the 0- and 1-hour sample. RESULTS Among 3254 patients, RD was present in 487 patients (15%). The
prevalence of non-ST-segment elevation myocardial infarction was substantially higher in patients with
RD compared with patients with normal renal function (31% versus 13%, P<0.001). Using hs-cTnT,
patients with RD had comparable sensitivity of rule-out (100.0% [95% confidence interval CI, 97.6-100.0]
versus 99.2% [95% CI, 97.6-99.8]; P=0.559), lower specificity of rule-in (88.7% [95% CI, 84.8-91.9] ver-
sus 96.5% [95% CI, 95.7-97.2]; P<0.001), and lower overall efficacy (51% versus 81%, P<0.001), mainly
driven by a much lower percentage of patients eligible for rule-out (18% versus 68%, P<0.001) compared
with patients with normal renal function. Using hs-cTnI, patients with RD had comparable sensitiv-
ity of rule-out (98.6% [95% CI, 95.0-99.8] versus 98.5% [95% CI, 96.5-99.5]; P=1.0), lower specificity of
rule-in (84.4% [95% CI, 79.9-88.3] versus 91.7% [95% CI, 90.5-92.9]; P<0.001), and lower overall efficacy
(54% versus 76%, P<0.001; proportion ruled out, 18% versus 58%, P<0.001) compared with patients
with normal renal function. CONCLUSIONS In patients with RD, the safety of the European Society
of Cardiology 0/1-hour algorithm is high, but specificity of rule-in and overall efficacy are decreased.
Modifications of the rule-in and rule-out thresholds did not improve the safety or overall efficacy of the
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BACKGROUND: The European Society of Cardiology recommends a 0/1-hour 
algorithm for rapid rule-out and rule-in of non–ST-segment elevation myocardial 
infarction using high-sensitivity cardiac troponin (hs-cTn) concentrations irrespective 
of renal function. Because patients with renal dysfunction (RD) frequently present 
with increased hs-cTn concentrations even in the absence of non–ST-segment 
elevation myocardial infarction, concern has been raised regarding the performance 
of the 0/1-hour algorithm in RD.
METHODS: In a prospective multicenter diagnostic study enrolling unselected 
patients presenting with suspected non–ST-segment elevation myocardial infarction to 
the emergency department, we assessed the diagnostic performance of the European 
Society of Cardiology 0/1-hour algorithm using hs-cTnT and hs-cTnI in patients with 
RD, defined as an estimated glomerular filtration rate <60 mL/min/1.73 m2, and 
compared it to patients with normal renal function. The final diagnosis was centrally 
adjudicated by 2 independent cardiologists using all available information, including 
cardiac imaging. Safety was quantified as sensitivity in the rule-out zone, accuracy as 
the specificity in the rule-in zone, and efficacy as the proportion of the overall cohort 
assigned to either rule-out or rule-in based on the 0- and 1-hour sample.
RESULTS: Among 3254 patients, RD was present in 487 patients (15%). The 
prevalence of non–ST-segment elevation myocardial infarction was substantially 
higher in patients with RD compared with patients with normal renal function (31% 
versus 13%, P<0.001). Using hs-cTnT, patients with RD had comparable sensitivity of 
rule-out (100.0% [95% confidence interval {CI}, 97.6–100.0] versus 99.2% [95% CI, 
97.6–99.8]; P=0.559), lower specificity of rule-in (88.7% [95% CI, 84.8–91.9] versus 
96.5% [95% CI, 95.7–97.2]; P<0.001), and lower overall efficacy (51% versus 81%, 
P<0.001), mainly driven by a much lower percentage of patients eligible for rule-out 
(18% versus 68%, P<0.001) compared with patients with normal renal function. 
Using hs-cTnI, patients with RD had comparable sensitivity of rule-out (98.6% [95% 
CI, 95.0–99.8] versus 98.5% [95% CI, 96.5–99.5]; P=1.0), lower specificity of rule-in 
(84.4% [95% CI, 79.9–88.3] versus 91.7% [95% CI, 90.5–92.9]; P<0.001), and 
lower overall efficacy (54% versus 76%, P<0.001; proportion ruled out, 18% versus 
58%, P<0.001) compared with patients with normal renal function.
CONCLUSIONS: In patients with RD, the safety of the European Society of 
Cardiology 0/1-hour algorithm is high, but specificity of rule-in and overall efficacy are 
decreased. Modifications of the rule-in and rule-out thresholds did not improve the 
safety or overall efficacy of the 0/1-hour algorithm.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT00470587.
0/1-Hour Triage Algorithm for Myocardial 
Infarction in Patients With Renal 
Dysfunction
Correspondence to: Christian 
Mueller, MD, Department of 
Cardiology, Cardiovascular 
Research Institute Basel, University 
Hospital Basel, Petersgraben 4, 
CH-4031 Basel, Switzerland. E-mail 
christian.mueller@usb.ch
Sources of Funding, see page 449
© 2017 The Authors. Circulation 
is published on behalf of the 
American Heart Association, Inc., 
by Wolters Kluwer Health, Inc. This 
is an open access article under the 
terms of the Creative Commons 
Attribution Non-Commercial-
NoDerivs License, which permits 
use, distribution, and reproduction 
in any medium, provided that the 
original work is properly cited, 
the use is noncommercial, and no 
modifications or adaptations are 
made.
Raphael Twerenbold, MD
et al
The full author list is available on 
page 448.
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
0/1-Hour Algorithm in Renal Dysfunction
Circulation. 2018;137:436–451. DOI: 10.1161/CIRCULATIONAHA.117.028901 January 30, 2018 437
ORIGINAL RESEARCH 
ARTICLE
Acute myocardial infarction (AMI) is a major cause of death and disability worldwide. Its rapid and accurate diagnosis is critical for the 
initiation of effective evidence-based medical manage-
ment and treatment.1–3 In addition, its rapid and reliable 
rule-out has the potential to reduce the time spent in 
the emergency department (ED), accelerate the identifi-
cation and treatment of the actual cause of chest pain, 
reduce patients’ anxiety, and avoid substantial costs for 
the healthcare system.4,5
For several reasons, patients with renal dysfunc-
tion merit particular attention.6,7 First, the incidence 
of AMI is increased in this vulnerable subgroup.8–10 
Second, atypical clinical presentation of AMI may be 
more frequent.11,12 Third, left ventricular hypertrophy 
is common and often results in ECG changes that may 
mimic or obscure AMI. Fourth, patients with renal dys-
function are more prone to adverse events related to 
cardiovascular medication (eg, anticoagulation) as well 
as cardiovascular procedures, including coronary an-
giography and coronary intervention.1,2 Fifth, levels of 
cardiac troponin (cTn) are frequently chronically elevat-
ed even in the absence of AMI.6,10,13 Recently, sensitive 
and high-sensitivity cardiac troponin assays (hs-cTn) 
were demonstrated to be accurate tools in diagnos-
ing AMI in patients with renal dysfunction, particularly 
when adjusted slightly higher cutoff levels are used for 
clinical decision making.10
The latest guidelines of the European Society of Car-
diology (ESC) for the management of acute coronary 
syndromes in patients presenting without persistent ST-
segment elevation recommend the use of a 0/1-hour al-
gorithm to rapidly rule out and rule in non–ST-segment 
elevation myocardial infarction (NSTEMI) based on hs-
cTn concentrations at presentation and their absolute 
1-hour changes.1 Assay-specific cutoff values are rec-
ommended for uniform application irrespective of re-
nal function. High safety and efficacy of the 0/1-hour 
algorithm were demonstrated in unselected patients, of 
which the vast majority had normal renal function. It is 
unknown whether these results also apply to patients 
with renal dysfunction (RD).1,14–19 Because patients with 
RD frequently present with increased hs-cTn concentra-
tions even in the absence of NSTEMI, concern has been 
raised regarding the performance of the 0/1-hour algo-
rithm in RD.10 
 We therefore aimed to assess the diagnostic perfor-
mance of the ESC 0/1-hour algorithm in patients with 
RD in a large prospective multicenter diagnostic study.
METHODS
Study Design and Population
APACE (Advantageous Predictors of Acute Coronary 
Syndrome Evaluation) is an ongoing prospective international 
multicenter diagnostic study with 12 centers in 5 European 
countries aiming to advance the early diagnosis of AMI 
(ClinicalTrials.gov. Unique identifier: NCT00470587).10,15–
17,20,21 Adult patients presenting to the ED with symptoms 
suggestive of AMI (eg, acute chest discomfort and angina 
pectoris) with an onset or peak within the last 12 hours 
were recruited. Enrollment was independent of renal func-
tion, whereas patients with terminal kidney failure on 
chronic dialysis were excluded. For this analysis, patients 
with ST-segment elevation myocardial infarction, patients 
with missing creatinine measurement, patients in whom the 
final diagnosis remained unclear even after central adjudica-
tion and ≥1 elevated hs-cTnT concentration possibly indicat-
ing AMI, as well as patients with no available hs-cTnT (for 
dataset A) or hs-cTnI (for dataset B) concentrations deter-
mined on presentation to the ED and after 1 hour were also 
excluded. Dataset B represents a subset of dataset A. The 
most common reasons for misvsing samples after 1 hour 
were early transfer to the catheter laboratory or coronary 
care unit and diagnostic procedures around the 1-hour win-
dow that precluded blood draw at 1 hour.
The study was carried out according to the principles of 
the Declaration of Helsinki and approved by the local eth-
ics committees. Written informed consent was obtained 
from all patients. The authors designed the study, gathered 
Clinical Perspective
What Is New?
• The 0/1-hour algorithms using high-sensitivity car-
diac troponin for rapid triage of patients with sus-
pected myocardial infarction are increasingly used 
in clinical practice worldwide.
• Although their high safety and efficacy could be 
shown in the general, mixed setting of emergency 
departments, their utility in patients with renal dys-
function, presenting with elevated high-sensitivity 
cardiac troponin levels often in the absence of 
acute myocardial ischemia, has been questioned.
• For the first time, we demonstrated the excellent 
safety of the 0/1-hour algorithms using high-sensi-
tivity cardiac troponin T and high-sensitivity cardiac 
troponin I also in patients with renal dysfunction, 
whereas overall efficacy and rule-in specificity were 
reduced compared with patients with normal renal 
function.
What Are the Clinical Implications?
• The investigated 0/1-hour algorithms for rapid tri-
age of patients with suspected myocardial infarc-
tion provide high safety irrespective of renal 
function and do not seem to require adjustment 
for renal function.
• However, the proportion of patients eligible for 
rule-out is reduced in patients with renal dysfunc-
tion compared with patients with normal renal 
function (≈ factor 3) because of the substantially 
higher prevalence of myocardial infarction in 
patients with renal dysfunction (≈ factor 3).
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and analyzed the data, vouched for the data and analysis, 
wrote the paper, and decided to publish. The STARD Checklist 
(Standards for Reporting of Diagnostic Accuracy Studies) can 
be found in Table I in the online-only Data Supplement.22 The 
data, analytic methods, and study materials will not be made 
available to other researchers for purposes of reproducing the 
results or replicating the procedure.
Routine Clinical Assessment
Patients underwent clinical assessment that included medi-
cal history, physical examination, and standard blood tests 
including serial measurements of local hs-cTn, 12-lead ECG, 
chest radiography, continuous ECG rhythm monitoring, and 
pulse oximetry. Management of patients was left to the dis-
cretion of the attending physician.
Adjudicated Final Diagnosis
Adjudication of the final diagnosis was performed by 2 inde-
pendent cardiologists at the core laboratory (University Hospital 
Basel) applying the universal definition of AMI using 2 data-
sets: (1) all available medical records obtained during clinical 
care, including history, physical examination, results of labora-
tory testing including serial clinical hs-cTn levels (according to 
onsite used hs-cTn assay obtained from clinical blood samples), 
radiological testing, ECG, echocardiography, cardiac exercise 
test, lesion severity, and morphology in coronary angiography 
pertaining to the patient from the time of ED presentation to 
90-day follow-up; and (2) study-specific assessments, including 
detailed chest pain characteristics using 34 predefined criteria, 
serial hs-cTnT blood concentrations obtained from study sam-
ples, and clinical follow-up by telephone or mail. In situations 
of disagreement about the diagnosis, cases were reviewed and 
adjudicated in conjunction with a third cardiologist.
AMI was defined and hs-cTn interpreted as recom-
mended in the current guidelines.1–3,14 In brief, myocardial 
infarction was diagnosed when there was evidence of myo-
cardial necrosis in association with a clinical setting con-
sistent with myocardial ischemia. Myocardial necrosis was 
diagnosed by ≥1 cTn value >99th percentile together with 
a significant rising or falling. The criteria used to define a 
rise or fall in conventional cTn and hs-cTnT are described 
in detail in the Methods section in the online-only Data 
Supplement. All other patients were classified in the cat-
egories of unstable angina, noncardiac chest pain, cardiac 
but noncoronary disease (eg, tachyarrhythmias, perimyo-
carditis), and symptoms of unknown origin with normal 
levels of hs-cTnT.
Assessment of Renal Function
Renal function was quantified by estimating glomerular filtra-
tion rate (eGFR) with the use of the chronic kidney disease 
epidemiology collaboration formula based on plasma creati-
nine level obtained at presentation to the ED, age, sex, and 
ethnicity.23 For this analysis, RD was defined as an eGFR of 
<60 mL/min/1.73 m.2 Creatinine measurements were per-
formed on a Roche Modular P1 analyzer with the enzymatic 
creatinine-peroxidase-antiperoxidase PAP method for quan-
tification (Roche Diagnostics). Serum creatinine can be con-
verted from micromoles per liter to milligrams per deciliter 
by dividing by 88.4. Preexisting kidney dysfunction was doc-
umented based on previous hospital records and detailed 
patient history at the time of ED presentation.
Investigational hs-cTn Measurements
Blood samples for determination of hs-cTnT and hs-cTnI were 
collected into tubes containing potassium EDTA (as an anti-
coagulant) or serum gel (as a clot activator) at presentation 
to the ED and serially thereafter. Serial sampling was dis-
continued when a patient was discharged or transferred to 
the catheter laboratory for treatment. After centrifugation, 
samples were either analyzed directly or frozen at ‒80°C until 
they were assayed in a blinded fashion in a dedicated core 
laboratory.
According to the manufacturer, the hs-cTnT assay (Elecsys 
2010 high-sensitivity troponin T, Roche Diagnostics) has a 
99th percentile concentration of 14 ng/L with a correspond-
ing coefficient of variation of 10% at 13 ng/L.24 Limit of blank 
and limit of detection have been determined to be 3 ng/L and 
5 ng/L. None of the hs-cTnT measurements in this analysis 
were affected by the 2010 to 2012 calibration shift.25–28
The hs-cTnI assay (ARCHITECT High Sensitive STAT 
Troponin I, Abbott Laboratories) has a 99th percentile con-
centration of 26.2 ng/L with a corresponding coefficient of 
variation of <5% and a limit of detection of 1.9 ng/L.29–31
 Distributions of the latest study blood samples accord-
ing to time since ED presentation and time since chest pain 
onset are listed in Tables II and III in the online-only Data 
Supplement.
ESC hs-cTn 0/1-Hour Algorithm
Recent studies have highlighted fundamental differences 
in mortality risk, pathophysiology, and benefit from early 
coronary angiography and intense dual-antiplatelet therapy 
between patients with NSTEMI and patients with true unsta-
ble angina (not including patients with small NSTEMIs missed 
by conventional cTn assays).1,32 Accordingly, the immediate 
task in the ED is to detect NSTEMI. Thus, the ESC 0/1-hour 
algorithm was designed to detect NSTEMI. The diagnosis of 
unstable angina is based on clinical assessment, ECG, and 
rule-out of NSTEMI in the ED, as well as cardiac imaging per-
formed either in-hospital or on an outpatient basis.1,32
The ESC hs-cTn 0/1-hour algorithm, which should always 
be used in conjunction with all clinical information available, 
including the ECG, triages patients presenting with suspected 
NSTEMI toward rule-out, observe, and rule-in based on assay-
specific levels of hs-cTn obtained at presentation and after 
1 hour (Figure I in the online-only Data Supplement).1 The 
assay-specific cutoff levels were derived in diagnostic stud-
ies enrolling unselected patients with mostly normal renal 
function.1,14–19
Main Outcome Measures
The coprimary outcome measures were safety of rule-out, 
accuracy of rule-in, and overall efficacy of the ESC 0/1-hour 
algorithm in patients with RD. Safety was quantified as sen-
sitivity for NSTEMI in the rule-out group, accuracy as specific-
ity for NSTEMI in the rule-in group, and overall efficacy as 
the proportion of patients triaged to either rule-out or rule-in 
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based on the 0- and 1-hour sample. Because prevalence of 
NSTEMI differs between patients with RD and patients with 
normal renal function,10 the negative predictive value (NPV) 
for NSTEMI in the rule-out group and the positive predictive 
value (PPV) in the rule-in group, which both depend on prev-
alence, were considered as secondary outcome measures. 
Additional secondary outcome measures included the propor-
tion of patients assigned directly to rule-out or rule-in based 
on the single hs-cTn concentration measured at presentation.
Subgroup analyses assessing the diagnostic performance 
of the 0/1-hour algorithm were performed in early presenters 
(≤2 hours after chest pain onset), in patients with preexisting 
and new onset of RD, in women and men, and in the dataset 
after exclusion of patients who were part of the initial deriva-
tion cohort of the 1-hour algorithms.
To extend and corroborate the concept of the ESC 0/1-
hour algorithm in patients with RD, diagnostic performance 
was further assessed using stepwise modified cutoff criteria 
optimized for patients with RD using hs-cTn concentrations at 
presentation or absolute changes within the first hour.
Follow-Up and Clinical End Points
Patients were contacted 3, 12, and 24 months after discharge 
by telephone calls or in written form. Information regarding 
death during follow-up was furthermore obtained from the 
patient’s hospital notes, the family physician’s records, and 
the national registry on mortality. The coprimary prognostic 
end points were overall survival after 30 days and 2 years. The 
secondary prognostic end point was major adverse cardiac 
events (MACEs), defined as the composite of all-cause mor-
tality, AMI (including index event), cardiogenic shock, ventric-
ular tachyarrhythmias, or higher degree atrioventricular block 
at 30 days.
Statistical Analysis
All data are expressed as medians (1st quartile, 3rd quartile) 
for continuous variables and for categorical variables as num-
bers and percentages. Continuous variables were compared 
with the Mann-Whitney U test, and categorical variables 
using the chi-square test or Fisher exact test as appropriate. 
Receiver operating characteristics curves were constructed 
to assess the discriminative performance throughout hs-cTn 
concentrations at presentation and their absolute changes in 
≤1 hour to diagnose NSTEMI. The comparison of independent 
areas under the receiver operating characteristics curve was 
performed as recommended by Hanley and McNeil.33
We used the cross tables derived by the application of 
the official ESC assay-specific cutoff criteria for rule-out or 
rule-in to calculate diagnostic performance parameters and 
their 95% confidence intervals (CI).34 To compare sensitivity, 
specificity, NPV, PPV, and efficacy, we used a chi-square or 
Fisher exact test for unpaired samples and the McNemar test 
or the method described by Moskowitz and Pepe35 for paired 
samples, as appropriate. Correlations between renal function 
and concentrations/changes of hs-cTn were determined with 
the use of the Spearman rank correlation based on log-trans-
formed hs-cTn values. 
Overall survival and MACE-free survival during follow-up 
according to the classification provided by the respective 0/1-
hour algorithm were plotted in Kaplan-Meier curves, and a 
log-rank test was used to assess differences in survival among 
groups.
Unless stated otherwise, results are reported based on 
dataset A. All hypothesis testing was 2-tailed, and P values 
of <0.05 were considered to indicate statistical significance 
without adjustments for multiple testing. All statistical analy-
ses were performed with the use of IBM SPSS Statistics for 
Windows, version 23.0 (SPSS Inc), R statistical software ver-
sion 3.4.1 (www.R-project.org, R Foundation for Statistical 
Computing), and MedCalc Statistical Software, version 17.8 
(MedCalc Software bvba).
RESULTS
Patient Characteristics
From 4323 consecutively recruited patients, serial hs-
cTnT measurements at presentation and after 1 hour 
were available in 3254 patients (dataset A, 100%) and 
serial hs-cTnI measurements in 2949 patients (dataset 
B) (Figure II in the online-only Data Supplement). Base-
line characteristics are depicted in the Table 1 and Table 
IV in the online-only Data Supplement. Dataset B rep-
resented a subset of dataset A (overlap, 91%) (Table V 
in the online-only Data Supplement). Prevalence of RD 
was 15% (487/3254 in dataset A, 445/2949 in dataset 
B) with a median eGFR of 48 (37, 55) ml/min/1.73 m2 as 
compared with 93 (81, 104) ml/min/1.73 m2 in patients 
with normal renal function. Patients with RD differed 
from patients with normal renal function in multiple 
baseline characteristics, including higher prevalence of 
cardiovascular risk factors, previous myocardial infarc-
tion, and ECG abnormalities.
Adjudicated Final Diagnosis
NSTEMI was the adjudicated final diagnosis in 515 of 
3254 (16%) patients. In patients with RD, prevalence 
of NSTEMI was 31% compared with 13% in patients 
with normal renal function (P<0.001). The prevalence 
of NSTEMI was significantly higher in those patients 
with RD who had preexisting kidney disease (37% ver-
sus 24%, P=0.002). Among all NSTEMIs, type 2 NSTEMI 
was more frequent in patients with RD compared with 
patients with normal renal function (22% versus 10%, 
P<0.001) (Table VI in the online-only Data Supple-
ment), resulting in an overall type 2 NSTEMI prevalence 
of 6.8% (33/487) in patients with RD compared with 
1.3% (35/2767) in patients with normal renal function. 
Also, cardiac causes other than coronary artery disease 
were more common in patients with RD and noncar-
diac causes less common compared with patients with 
normal renal function. Disagreement between the 2 
independent cardiologists adjudicating the final diag-
nosis was more common in patients with RD compared 
with patients with normal renal function (13.1% versus 
9.1%, P=0.006).
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Hs-cTn Concentrations at Presentation 
and 1-Hour Changes According to Renal 
Function and Final Diagnosis
In patients with RD and patients with normal renal 
function, hs-cTn concentrations at presentation as well 
as absolute 1-hour changes were significantly higher in 
NSTEMI compared with other final diagnoses (P<0.001 
for all comparisons, data not shown).
In patients with final diagnoses other than NSTEMI, 
hs-cTnT and hs-cTnI concentrations at presentation as 
well as absolute 1-hour changes showed a strong, in-
verse correlation with eGFR, which was not observed in 
NSTEMI (Figure III in the online-only Data Supplement). 
Table 1. Baseline Characteristics of Patients in Dataset A
 
Normal Renal 
Function
Renal 
Dysfunction*  
Renal Dysfunction (n=487)
NSTEMI
n=2767 n=487 P Value† Yes (n=151) No (n=336) P Value‡
Age, y 58 (47, 70) 79 (73, 84) <0.001 81 (75, 86) 78 (72, 83) 0.001
Sex, male 1924 (70) 284 (58) <0.001 93 (62) 191 (57) 0.326
Risk factors
  Hypertension 1554 (56) 347 (71) <0.001 140 (93) 299 (89) 0.202
  Hypercholesterolemia 1258 (45) 347 (71) <0.001 117 (77) 230 (68) 0.042
  Diabetes mellitus 434 (16) 136 (28) <0.001 51 (34) 85 (25) 0.054
  Current smoking 770 (28) 44 (9) <0.001 19 (13) 25 (7) 0.067
  History of smoking 1001 (36) 223 (46) <0.001 69 (46) 154 (46) 0.977
History
  Coronary artery disease 811 (29) 280 (57) <0.001 102 (68) 178 (53) 0.003
  Previous myocardial infarction 576 (21) 204 (42) <0.001 82 (54) 122 (36) <0.001
  Previous revascularization 695 (25) 209 (43) <0.001 73 (48) 136 (40) 0.105
  Peripheral artery disease 110 (4) 62 (13) <0.001 26 (17) 36 (11) 0.046
  Previous stroke 123 (4) 58 (12) <0.001 23 (15) 35 (10) 0.129
Vital status
  Heart rate, bpm 76 (66, 89) 75 (64, 91) 0.519 81 (70, 97) 73 (63, 88) 0.001
  Systolic blood pressure, mm Hg 142 (127, 158) 138 (121, 156) 0.001 135 (123, 157) 139 (121, 156) 0.556
  Diastolic blood pressure, mm Hg 82 (73, 92) 73 (64, 84) <0.001 73 (63, 83) 74 (64, 85) 0.549
  Body mass index, kg/m2 26 (24, 30) 27 (24, 30) 0.285 26 (23, 28) 27 (25, 31) <0.001
Electrocardiographic findings
  Left bundle-branch block 76 (3) 48 (10) <0.001 21 (14) 27 (8) 0.044
  ST-segment depression 192 (7) 74 (15) <0.001 38 (25) 36 (11) <0.001
  T-wave inversion 288 (10) 84 (17) <0.001 37 (25) 47 (14) 0.004
Laboratory measurements
  Serum creatinine, μmol/l 73 (63, 83) 118 (101, 140) <0.001 123 (106, 151) 116 (99, 135) 0.002
  Estimated GFR ml/min/1.73 m2 93 (81, 104) 48 (37, 55) <0.001 45 (34, 52) 49 (39, 55) <0.001
Hours since CPO 5 (2, 14) 6 (3, 12) 0.018 6 (3, 12) 6 (3, 14) 0.417
Distribution of time since CPO
  ≤2 h after CPO 731 (27) 97 (20) 0.002 35 (23) 62 (19)
0.550
  ≤3 h after CPO 1031 (37) 144 (30) <0.001 47 (32) 97 (29)
  >3 h to ≤6 h after CPO 561 (20) 117 (24) 0.060 37 (25) 80 (24)
  >6 h after CPO 1158 (42) 226 (46) 0.146 67 (44) 159 (47)
CPO indicates chest pain onset; GFR, glomerular filtration rate; and NSTEMI, non–ST-segment elevation myocardial infarction. Categorical variables are presented 
as numbers (%); continuous variables are presented as medians (quartile 1, quartile 3). Continuous variables were compared with the Mann-Whitney U test and 
categorical variables using the Pearson chi-square test or Fisher exact test as appropriate.
*Renal dysfunction was diagnosed if the estimated GFR was <60 mL/min/1.73 m2 using the chronic kidney disease epidemiology collaboration formula based on 
plasma creatinine levels obtained at presentation to the emergency department, age, sex, and ethnicity.
†For comparisons between patients with normal renal function and renal dysfunction.
‡For comparisons between patients with and without acute myocardial infarction in the subset of patients with renal dysfunction.
 by guest on M
arch 8, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
0/1-Hour Algorithm in Renal Dysfunction
Circulation. 2018;137:436–451. DOI: 10.1161/CIRCULATIONAHA.117.028901 January 30, 2018 441
ORIGINAL RESEARCH 
ARTICLE
The diagnostic accuracy of hs-cTnT and hs-cTnI concen-
trations at presentation for NSTEMI, as quantified by 
the areas under the receiver operating characteristics 
curve, was high among patients with RD (for hs-cTnT, 
0.87 [95% CI, 0.84–0.90]; for hs-cTnI, 0.86 [95% CI, 
0.83–0.90]) but even significantly higher in patients 
with normal renal function (for hs-cTnT, 0.94 [95% CI, 
0.93–0.95]; for hs-cTnI, 0.93 [95% CI, 0.92–0.95]) (Fig-
ure IV in the online-only Data Supplement). Smaller dif-
ferences were observed for the diagnostic accuracy of 
the absolute 1-hour change in hs-cTn.
Performance of the ESC 0/1-Hour 
Algorithm Using hs-cTnT in RD
Safety of rule-out by the ESC 0/1-hour algorithm, 
quantified as the sensitivity for NSTEMI in the rule-out 
group, was high in patients with RD and similar to 
Table 2. Performance of the European Society of Cardiology 0/1-Hour Algorithm in Patients 
With Renal Dysfunction and Normal Renal Function
Using High-Sensitivity Cardiac Troponin T 
Renal Dysfunction  
(n=487)
Normal Renal Function 
(n=2767)
P 
Value*
Prevalence of NSTEMI 31 13 <0.001
Sensitivity of rule-out 100.0 (97.6–100.0) 99.2 (97.6–99.8) 0.559
NPV of rule-out 100.0 (n.a.) 99.8 (99.5–100.0) 1.0
Specificity of rule-in 88.7 (84.8–91.9) 96.5 (95.7–97.2) <0.001
PPV of rule-in 76.5 (70.6–81.6) 77.1 (73.1–80.7) 0.886
Proportion ruled out 18.1 (14.6–21.6) 67.9 (66.4–69.6) <0.001
  Based on 0-hour sample only 1.4 (0.4–2.6) 17.9 (16.6–19.3) <0.001
  Based on 0/1-hour samples 16.6 (13.5–20.0) 50.0 (48.2–51.9) <0.001
Proportion ruled in 33.3 (29.3–37.5) 13.3 (12.0–14.6) <0.001
  Based on 0-hour sample only 25.9 (22.4–29.7) 8.0 (7.0–9.0) <0.001
  Based on 1-hour change 7.4 (5.2–9.6) 5.3 (4.5–6.1) 0.066
Overall efficacy 51.3 (46.8–55.8) 81.2 (79.8–82.6) <0.001
Prevalence of NSTEMI in the observational group 11 (7–15) 15 (12–18) 0.186
Numbers represent percentage (95% confidence interval). 
n.a. indicates not applicable; NPV, negative predictive value; NSTEMI, non–ST-segment elevation myocardial infarction; and PPV, 
positive predictive value. *Performances measures in patients with renal dysfunction and normal renal function were compared using 
the chi-square or Fisher exact test.
Table 3. Performance of the European Society of Cardiology 0/1-Hour Algorithm in Patients 
With Renal Dysfunction and Normal Renal Function
Using High-Sensitivity Cardiac Troponin I
Renal Dysfunction  
(n=445)
Normal Renal Function  
(n=2504) P Value
Prevalence of NSTEMI 32 13 <0.001
Sensitivity of rule-out 98.6 (95.0–99.8) 98.5 (96.5–99.5) 1.0
NPV of rule-out 97.4 (90.5–99.4) 99.7 (99.2–99.9) 0.046
Specificity of rule-in 84.4 (79.9–88.3) 91.7 (90.5–92.9) <0.001
PPV of rule-in 70.8 (64.8–76.2) 60.7 (57.1–64.2) 0.023
Proportion ruled out 17.5 (13.9–21.4) 57.8 (55.8–59.8) <0.001
  Based on 0-hour sample only 1.3 (0.4–2.5) 10.9 (9.7–12.1) <0.001
  Based on 0/1-hour samples 16.2 (12.7–19.7) 46.9 (44.7–48.9) <0.001
Proportion ruled in 36.2 (31.6–40.8) 18.3 (16.8–19.8) <0.001
  Based on 0-hour sample only 27.0 (23.1–30.9) 12.9 (11.5–14.2) <0.001
  Based on 1-hour change 9.2 (6.5–12.0) 5.4 (4.6–6.4) 0.002
Overall efficacy 53.5 (49.2–58.0) 76.1 (74.5–77.8) <0.001
Prevalence of NSTEMI in the observational group 13 (9–18) 8 (6–10) 0.021
Numbers represent percentage (95% confidence interval). 
n.a. indicates not applicable; NPV, negative predictive value; NSTEMI, non–ST-segment elevation myocardial infarction; and PPV, 
positive predictive value. *Performances measures in patients with renal dysfunction and normal renal function were compared using 
the chi-square or Fisher exact test.
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patients with normal renal function using hs-cTnT 
(100% [95% CI, 97.6–100] versus 99.2% [95% CI, 
97.6–99.8], respectively; P=0.559) (Table 2 and Fig-
ure 1). NPV was 100% in patients with RD compared 
with 99.8% (95% CI, 99.5–100) in patients with nor-
mal renal function (P=1.0).
Accuracy of rule-in, quantified as the specificity for 
NSTEMI in the rule-in group, was lower in patients 
with RD compared with patients with normal renal 
function (88.7% [95% CI, 84.8–91.9] versus 96.5% 
[95% CI, 95.7–97.2], P<0.001). Because of the higher 
prevalence of NSTEMI in patients with RD, accuracy of 
rule-in as quantified by PPV remained comparable in 
patients with RD and patients with normal renal func-
tion (PPV, 76.5% [95% CI, 70.6–81.6] versus 77.1% 
[95% CI, 73.1–80.7], P=0.886). Unstable angina (n=2 
and 1), myocarditis (n=0 and 14), Tako-Tsubo cardio-
myopathy (n=1 and 4), and acute heart failure (n=11 
and 6) accounted for 37% and 30% of non-NSTEMI 
diagnoses in the rule-in groups of patients with RD 
and normal renal function, respectively (P=0.445 for 
comparison).
Efficacy of rule-out, quantified as the proportion of 
patients assigned toward rule-out based on the 0- and 
1-hour samples, was substantially lower in patients 
with RD compared with patients with normal renal 
function (18.1% [95% CI, 14.6–21.6] versus 67.9% 
[95% CI, 66.4–69.6], P<0.001). Direct rule-out, based 
on a single hs-cTn concentration measured at pre-
sentation in patients presenting >3 hours after chest 
pain onset, was feasible in 1.4% (95% CI, 0.4–2.6) 
of patients with RD compared with 17.9% (95% CI, 
16.6–19.3) of patients with normal renal function 
(P<0.001). Efficacy of rule-in was substantially higher 
in patients with RD compared with patients with nor-
mal renal function (33.3% [95% CI, 29.3–37.5] versus 
A
B
Figure 1. Performance of the European Society of Cardiology 0/1-hour algorithm using high-sensitivity cardiac 
troponin T in patients with renal dysfunction and normal renal function.  
Flow charts depicting the diagnostic performance of the European Society of Cardiology 0/1-hour algorithm for rule-out and 
rule-in of non–ST-segment elevation myocardial infarction in (A) patients with renal dysfunction (defined as an estimated 
glomerular filtration rate <60 mL/min/1.73 m2), and (B) patients with normal renal function using high-sensitivity cardiac 
troponin T (hs-cTnT, Elecsys analyzer). 1h-change indicates absolute (unsigned) change of high-sensitivity cardiac troponin 
within 1 hour; n.a., not applicable; NPV, negative predictive value; NSTEMI, non–ST-segment elevation myocardial infarction; 
PPV, positive predictive value; Sens, Sensitivity; and Spec, specificity. *If chest pain onset >3 hours before presentation to the 
emergency department.
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13.3% [95% CI, 12.0–14.6], P<0.001). Overall effica-
cy, quantified as the proportion of patients assigned to 
either rule-out or rule-in in ≤1 hour, was substantially 
lower in patients with RD compared with patients with 
normal renal function (51.3% [95% CI, 46.8–55.8] 
versus 81.2% [95% CI, 79.8–82.6], P<0.001). Preva-
lence of NSTEMI in the observe group was comparable 
in patients with RD compared with patients with nor-
mal renal function (11% versus 15%, P=0.186). No 
NSTEMI patient with RD was incorrectly ruled out by 
the ESC 0/1-hour algorithm, whereas 3 NSTEMI pa-
tients (0.1%) with normal renal function were missed 
(Table VII in the online-only Data Supplement). The 
diagnostic performance of the ESC hs-cTnT 0/1-hour 
algorithm according to different stages of renal dys-
function is depicted in Figure 2.
Performance of the ESC 0/1-Hour 
Algorithm Using hs-cTnI in RD
Safety of rule-out by the ESC 0/1-hour algorithm was 
high in patients with RD and similar to patients with 
normal renal function using hs-cTnI (98.6% [95% CI, 
95.0–99.8] versus 98.5% [95% CI, 96.5–99.5], re-
spectively; P=1.0) (Table 3 and Figure 3). NPV (and the 
prevalence of non-NSTEMI) was lower in patients with 
RD (NPV, 97.4% [95% CI, 90.5–99.4]) compared with 
patients with normal renal function (NPV, 99.7% [95% 
CI, 99.2–99.9], P=0.046).
Accuracy of rule-in as quantified by specificity was 
lower in patients with RD compared with patients with 
normal renal function (specificity, 84.4% [95% CI, 79.9–
88.3] versus 91.7% [95% CI, 90.5–92.9], P<0.001). 
Figure 2. Performance of the European Society of Cardiology 0/1-hour algorithm using high-sensitivity cardiac 
troponin T in different stages of renal function. 
hs-cTnT indicates high-sensitivity cardiac troponin T; and NSTEMI, non–ST-segment elevation myocardial infarction.
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However, because of the higher prevalence of NSTEMI 
in patients with RD, accuracy as quantified by PPV of 
rule-in was higher in patients with RD compared with 
patients with normal renal function (PPV, 70.8% [95% 
CI, 64.8–76.2] versus 60.7% [95% CI, 57.1–64.2], 
P=0.023). Unstable angina (n=8 and 30), myocarditis 
(n=0 and 15), Tako-Tsubo cardiomyopathy (n=1 and 4), 
and acute heart failure (n=10 and 15) accounted for 
40% and 36% of non-NSTEMI diagnoses in the rule-in 
groups of patients with RD and patients with normal 
renal function, respectively (P=0.614 for comparison).
Efficacy of rule-out was substantially lower in pa-
tients with RD compared with patients with normal 
renal function (17.5% [95% CI, 13.9–21.4] versus 
57.8% [95% CI, 55.8–59.8], P<0.001). Direct rule-out 
was feasible in 1.3% (95% CI, 0.4–2.5) of patients 
with RD compared with 10.9% (95% CI, 9.7–12.1) of 
patients with normal renal function (P<0.001). Efficacy 
of rule-in was higher in patients with RD  compared 
with patients with normal renal function (36.2% [95% 
CI, 31.6–40.8] versus 18.3% [95% CI, 16.8–19.8], 
P<0.001). Overall efficacy was substantially lower in pa-
tients with RD compared with patients with normal re-
nal function (53.5% [95% CI, 49.2–58.0] versus 76.1% 
[95% CI, 74.5–77.8], P<0.001). Prevalence of NSTEMI 
in the observational group was lower in patients with 
RD compared with patients with normal renal function 
(13% versus 18%, P=0.021). Two patients with NSTEMI 
(0.4%) with RD were incorrectly ruled out by the ESC 
0/1-hour algorithm, whereas 5 patients with NSTEMI 
(0.2%) with normal renal function were missed (Table 
VIII in the online-only Data Supplement). Diagnostic 
performance of the ESC hs-cTnI 0/1-hour algorithm ac-
cording to different stages of RD is depicted in Figure 4.
Performance of the ESC 0/1-Hour 
Algorithm in Different Subgroups
Robust and highly comparable findings were observed 
in subgroup and sensitivity analyses performed in pa-
A
B
Figure 3. Performance of the European Society of Cardiology 0/1-hour algorithm using high-sensitivity cardiac troponin 
I in patients with renal dysfunction and normal renal function. 
Flow charts depicting the diagnostic performance of the European Society of Cardiology 0/1-hour algorithm for rule-out and rule-in 
of non–ST-segment elevation myocardial infarction in patients with (A) renal dysfunction and (B) normal renal function using high-
sensitivity cardiac troponin I (hs-cTnI, Architect analyzer). 1-h change indicates absolute (unsigned) change of high-sensitivity cardiac 
troponin within 1 hour; NPV, negative predictive value; NSTEMI, non–ST-segment elevation myocardial infarction; PPV, positive pre-
dictive value; Sens, sensitivity; and Spec, specificity. *If chest pain onset >3 hours before presentation to the emergency department.
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tients presenting within the first 2 hours after chest 
pain onset, in patients with preexisting and new-onset 
of renal dysfunction, and in women and men as well 
as in the study dataset after exclusion of patients who 
were part of the original derivation cohorts of the 2 
investigated 0/1-hour algorithms. Details on the diag-
nostic performance of the ESC 0/1-hour algorithms in 
the various subgroups are listed in Tables IX‒XII in the 
online-only Data Supplement.
Modifications of the 0/1-Hour Algorithm 
to Optimize Rule-Out Efficacy and Rule-In 
Specificity in Patients With RD
Stepwise increase of the official ESC assay-specific 
cutoff criteria for rule-out of NSTEMI resulted in in-
creasing rule-out efficacy, however at the cost of rule-
out safety. Stepwise increase of the official ESC assay-
specific cutoff criteria for rule-in of NSTEMI resulted in 
increasing specificity of rule-in, however at the cost of 
rule-in efficacy (Tables XIII and XIV in the online-only 
Data Supplement). Among the numerous possible 
cutoff criteria combinations, 1 specific cutoff value 
combination for rule-out, preserving the same sensi-
tivity as the official ESC cutoff value combination, as 
well as 1 specific cutoff value combination for rule-
in, was chosen for each hs-cTn assay to compare its 
performance with the official ESC 0/1-hour algorithm 
(Table XV and Figures V and VI in the online-only Data 
Supplement). Cutoff concentrations optimized for RD 
increased rule-out efficacy and rule-in specificity by 
4.5% (P<0.001) and 3.9% (P<0.001), respectively, for 
hs-cTnT and by 4.7% (P<0.001) and 3.7%, (P=0.001) 
respectively, for hs-cTnI. However, because improved 
Figure 4. Performance of the European Society of Cardiology 0/1-hour algorithm using high-sensitivity cardiac 
troponin I in different stages of renal function.  
hs-cTnI indicates high-sensitivity cardiac troponin I; and NSTEMI, non–ST-segment elevation myocardial infarction.
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rule-in specificity was obtained at the cost of rule-in 
efficacy, overall efficacy could not be optimized with 
the modified 0/1-hour algorithm (for hs-cTnT, ‒1.0%, 
P=0.568; for hs-cTnI, +1.1%, P=0.500).
Prognostic Performance of the ESC 0/1-
Hour Algorithm
Median follow-up time was 749 days (418, 847). Es-
timated overall-survival was 99.2% at 30 days and 
94.3% at 2 years. Particularly in patients with RD, the 
ESC 0/1-hour algorithm using hs-cTnT and hs-cTnI al-
lowed a powerful discrimination between high versus 
moderate and low probability of short-term (30 days) 
and midterm (2 years) overall survival and short-term 
(30 days) MACE-free survival in the respective rule-
out, observe, and rule-in groups (all log-rank P values 
<0.001) (Figure 5 and Figure VII in the online-only Data 
Supplement).
DISCUSSION
This prospective, multicenter diagnostic study enrolling 
unselected patients presenting with acute chest dis-
comfort to the ED used central adjudication to assess 
the performance of the ESC 0/1-hour algorithm in pa-
tients with RD. We report 8 major findings.
 First, patients with RD presenting with acute chest 
discomfort to the ED had NSTEMI >2 times as often and 
type 2 NSTEMI even >5 times as often as patients with 
normal renal function. This observation extends and 
corroborates previous studies indicating that RD is not 
only commonly associated with coronary artery disease 
but also hypertensive heart disease and other structural 
cardiac disorders prone to developing the triggers of 
type 2 myocardial infarction, such as tachyarrhythmias, 
hypertension, and anemia.8–10,36,37
Second, hs-cTn concentrations at presentation and 
their absolute 1-hour changes correlated strongly and 
inversely with eGFR in patients with diagnoses other 
than NSTEMI but not NSTEMI. Third, in patients with 
RD, the diagnostic performance of hs-cTn concentra-
tions at presentation was high (areas under the re-
ceiver operating characteristics curve, 0.86–0.87) and 
further increased on using absolute 1-hour hs-cTn 
changes (areas under the receiver operating charac-
teristics curve, 0.88–0.92). 
Fourth, and likely of utmost importance, the safe-
ty of the official ESC 0/1-hour algorithm was high in 
patients with RD (sensitivity, 98.6‒100) and compara-
ble to patients with normal renal function (sensitivity, 
98.5–99.2) irrespective of whether hs-cTnT or hs-cTnI 
was used. However, the efficacy of rule-out was sub-
stantially reduced in patients with RD and allowed the 
early rule-out in 18% of patients only. 
Fifth, because of the higher proportions of patients 
with elevated levels of hs-cTn even in the absence of 
NSTEMI, specificity of rule-in was lower in patients with 
RD (84.4–88.7) compared with patients with normal renal 
function (91.7–96.5). However, the higher prevalence of 
NSTEMI in patients with RD also increased rule-in efficacy 
while maintaining high PPV of rule-in. The performance 
measures (mainly the PPV) of the ESC hs-cTnT 0/1-hour al-
gorithm and the ESC hs-cTnI 0/1-hour algorithm showed 
subtle but consistent differences to the advantage of hs-
cTnT. These differences are at least in part caused by the 
fact that serial measurements of hs-cTnT but not hs-cTnI 
were part of the extensive clinical information available 
for the adjudication of the final diagnosis in all patients. 
Accordingly, our methodology provided the most accu-
rate and valid estimates for the ESC hs-cTnT 0/1-hour 
algorithm but possibly slightly underestimated the true 
performance of the ESC hs-cTnI 0/1-hour algorithm. 
Sixth, overall efficacy allowing triage toward rule-out 
or rule-in based on the 0/1-hour samples was substan-
tially reduced in patients with RD (51.3–53.5) compared 
with patients with normal renal function (76.1–81.2). 
This difference was driven by the substantial reduc-
tion in rule-out efficacy that could only partly be com-
pensated for by the increase of rule-in efficacy. As a 
consequence, the percentage of patients remaining in 
the observe zone and usually requiring additional di-
agnostic tests including a 3-hour sample of hs-cTn and 
cardiac imaging is nearly twice as high in patients with 
RD compared with patients with normal renal function. 
Seventh, using slightly higher cutoff concentrations 
of hs-cTn as an attempt to increase rule-out efficacy and 
rule-in specificity only partly helped to overcome the 
challenges posed by RD. The high pretest probability for 
NSTEMI in patients with RD challenges the derivation of 
an alternative 0/1-hour algorithm that would balance 
rule-out efficacy and rule-in specificity substantially better 
than the official ESC 0/1-hour algorithm without losing 
safety. It is a matter of debate how much increase of rule-
out efficacy at the cost of rule-out safety or how much 
increase of rule-in specificity at the cost of rule-in efficacy 
would be acceptable. The use of alternative cutoff crite-
ria combinations yielded rather small improvements even 
though they were tested in a derivation setting unblinded 
to the outcome NSTEMI. Accordingly, the observed small 
improvements in efficacy when using alternative cutoffs 
are associated with a potential systematic bias toward 
overestimating the real improvements, which might be 
even smaller in subsequent external validation in an in-
dependent study. Therefore, and because safety and 
simplicity are the most important characteristics of any 
diagnostic algorithm, the findings of this study recom-
mend the use of the official ESC 0/1-hour algorithm in 
patients with RD until information technology-based de-
cision tools integrating all available information (eg, age, 
sex, serial hs-cTn measurements, renal function) become 
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Figure 5. Short- and midterm survival according to risk stratification group by the European Society of Cardiology 
0/1-hour algorithm using high-sensitivity cardiac troponin T and I in patients with normal renal function and renal 
dysfunction.  
Kaplan-Meier curves depicting overall survival within 30 and 720 days for patients with normal renal function (dashed lines) 
and renal dysfunction (solid lines) stratified by the European Society of Cardiology 0/1-hour algorithm to the rule-out (green 
lines), observational (orange lines), and rule-in (red lines) groups. A, Using high-sensitivity cardiac troponin T. B, Using high-
sensitivity cardiac troponin I.
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available in clinical routine. The PPV for NSTEMI in pa-
tients assigned toward rule-in and thereby early coronary 
angiography would still be considered high enough by 
most experts, particularly given the difficulty of obtain-
ing similar diagnostic certainty in patients with moderate 
elevations in cTn without coronary angiography.
Eighth, the ESC 0/1-hour algorithm allowed a pow-
erful discrimination between high versus moderate 
and lower probability of short- and midterm overall 
survival as well as short-term MACE-free survival in the 
respective rule-out, observe, and rule-in groups also 
in patients with RD. The rather high rate of all-cause 
mortality during follow-up and MACE within 30 days 
of patients in the observe zone can be explained by the 
high incidence of chronic diseases in those patients, 
such as chronic heart failure, which are associated with 
high rates of both overall mortality and MACE within 
30 days. These findings extend and corroborate previ-
ous studies addressing the multitude of major unmet 
clinical needs in the often elderly patients with RD.8–10,38
Many of these challenges are related to the high 
prevalence of common yet undiagnosed cardiac co-
morbidities including hypertensive heart disease and 
diabetic cardiomyopathy associated with chronic cardio-
myocyte injury and therefore increases in hs-cTn plasma 
concentrations and an increased prevalence of ECG 
abnormalities in patients with RD. The exact underlying 
pathophysiological mechanisms are incompletely un-
derstood. The contribution of cardiomyocyte injury to 
elevated plasma concentrations of hs-cTn in RD seems 
to be far greater than that of impaired renal clearance, 
particularly because the molecular size of the intact mol-
ecule is too large to be filtrated by glomeruli.36,37,39–41 
Although cTn molecules may be degraded into smaller 
fragments that are small enough to be filtered by the 
kidney,42 the renal elimination and half-life of these cTn 
fragments seem to be similar in patients with RD and 
patients with normal renal function.43 In addition, in 
patients with end-stage renal disease and only minimal 
remaining endogenous renal function, successful renal 
transplantation leads to a substantial reduction and of-
ten normalization of serum creatinine but no relevant 
change in plasma concentrations of cTnI.39 It has been 
hypothesized that the underlying mechanism of chronic 
cTn release is associated with a cardiorenal syndrome 
triggered by some inflammatory processes leading to 
chronic cardiomyocyte injury and cTn release in RD.44,45
Initial pilot studies evaluating the use of single cut-
off concentrations suggested that in patients with RD, 
adjusted higher hs-cTn concentrations might provide a 
better balance between sensitivity and specificity com-
pared with the 99th percentiles or the optimal single-
cutoff concentration derived in patients with normal 
renal function.10 Meanwhile, the clinical use of hs-cTn 
has advanced, and current guidelines recommend the 
integrated use of baseline hs-cTn concentrations and 
their absolute changes during serial sampling, as incor-
porated in the ESC 0/1-hour algorithm.1 In contrast to 
a single cutoff strategy, the ESC 0/1-hour algorithm tri-
ages patients toward 1 of 3 strata: rule-out, observe, or 
rule-in. Assessing the possible use of adjusted higher 
hs-cTn concentrations within this state-of-the-art con-
cept in patients with RD revealed pros and cons.
To the best of our knowledge, this is the first study 
investigating in detail the diagnostic performance of the 
ESC 0/1-hour algorithm in the vulnerable patient popu-
lation with RD, extending the excellent performance 
characteristics observed in patients with overwhelm-
ingly normal renal function.16–21 We cannot generalize 
our findings to patients with terminal kidney failure on 
chronic dialysis because they were excluded from this 
study. Additionally, our study was conducted in patients 
at the ED with symptoms suggestive of AMI. Further 
studies are required to quantify the utility of the ESC 
0/1-hour algorithm in patients with either higher (eg, in 
a coronary care unit setting) or lower (eg, in a general 
practitioner setting) pretest probability for AMI.
Some limitations merit consideration when interpret-
ing these findings. First, although we used the most strin-
gent methodology to adjudicate the presence or absence 
of NSTEMI, including central adjudication by experienced 
cardiologists, imaging, and serial measurements of hs-
cTn, we still may have misclassified a small number of 
patients.3,14 Second, to reflect the clinical information 
available to the ED physician when interpreting hs-cTn 
concentrations, we classified RD according to eGFR based 
on the serum creatinine concentrations obtained at ED 
presentation. Accordingly, this classification differs from 
the definition of chronic kidney disease, which would re-
quire RD to be present for 3 months.46 Third, the chronic 
kidney disease epidemiology collaboration formula was 
used to estimate GFR irrespective of age. However, the 
chronic kidney disease epidemiology collaboration for-
mula was primarily validated in patients <70 years of age.
In conclusion, in patients with RD, the safety of the 
ESC 0/1-hour algorithm is high, but the specificity of 
rule-in and overall efficacy are decreased. Modifications 
of cutoffs can only partly overcome the challenges of RD.
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Dr. Carolyn Lam:  Welcome to Circulation On The Run. Your weekly podcast summary and 
backstage pass to the journal and its editors. I'm Dr. Carolyn Lam, associate 
editor from the National Heart Center and Duke National University of 
Singapore. 
  In just a moment, we are going to be discussing the diagnostic conundrum of 
elevated high sensitivity cardiac troponin levels in a patient with renal disease, 
but also suspected of acute coronary syndrome. Aha! I bet I caught your 
attention. A very, very familiar diagnostic dilemma. So stay tuned right after 
these summaries. 
  Cardiac allograft vasculopathy is the leading cause of death in patients more 
than five years post cardiac transplantation. It has been hypothesized that 
cardiac allograft vasculopathy results from interrupted lymphatic drainage post 
surgery. Since the donor lymphatic vessels are not inesthimozed to that of the 
recipient during transplantation, thus the lymphatic system may play a crucial 
role in the alloimmune response. 
  Well, these hypothesis are addressed in the first paper in today's journal from 
first author Dr. Edwards, corresponding author Dr. Wong and colleagues from 
Kings College, London. These authors use spect CT lymphoscintigraphy in a pre‐
clinical model. And therefore provided objective quantification of lymphatic 
flow following transplantation and showed that this correlated to cardiac 
allograft vasculopathy. They demonstrated that cardiac lymphatic remodeling 
and lymphatic transport dysfunction post transplant was associated with cardiac 
allograft vasculopathy and transplant rejection.  
  They further showed that lymphatic flow was increased during chronic 
rejection. This in turn may have resulted in enhanced trafficking of antigen 
presenting cells to the local draining lymph nodes in an augmented alloimmune 
response. Now although the cause and effect of this phenomenon could not be 
fully established, these data provided the impetus for the investigation of 
lymphangiogenesis inhibition as a means to dampen chronic rejection.  
  The absorb bioresorbable vascular scaffold is known to completely resolve 
within three years after coronary artery implantation. However, what is the 
safety and effectiveness of these bioresorbable scaffolds during this critical 
three year period. First author Dr. Ali, corresponding author Dr. Stone and 
colleagues from Columbia University Medical Center performed an individual 
patient level meta analysis of the four randomized absorb trial and 
demonstrated that compared with metallic everolimus eluting stents, the 
bioresorbable vascular scaffold had higher rates of target lesion failure and 
device thrombosis cumulatively to three years and between one and three 
years. Multi‐variable analysis identified the number of treated lesions, current 
tobacco use and previous cardiac interventions as independent predictors of 
three year target lesion failure. Whereas diabetes was predictive of three year 
device thrombosis in bioresorbable vascular scaffold treated patients. 
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  The next paper reported the three year follow up of the FAME 2 trial, which 
compared PCI guided bi‐fractional flow reserve with best medical therapy in 
patients with stable coronary artery disease to assess clinical outcomes and cost 
effectiveness. First and corresponding author Dr. Fearon and colleagues from 
Stanford cardiovascular institute showed that major adverse cardiac events at 
three years were significantly lower in the PCI group, compared with the 
medical treatment group. This difference was primarily as a result of a lower 
rate of urgent revascularization. Mean initial costs were higher in the PCI group, 
but by three years, were similar between the two groups. The incremental cost 
effectiveness ratio for PCI compared to medical therapy was more than $17,000 
per quality adjusted life year at two years and $1,600 per quality adjusted life 
year at three years. Thus the authors concluded that percutaneous coronary 
intervention in patients with stable coronary artery disease and at normal 
fractional flow reserve may be advantages compared to with medical therapy 
alone, because it results in improved clinical outcomes and quality of life at no 
increased cost by the end of three years follow up. 
  The next study shows for the first time, that pioglitazone may prevent stroke as 
a single stand‐alone outcome. Today's paper by first author Dr. Yaghi, 
corresponding author Dr. Kernan from Yale School of Medicine and colleagues 
was a secondary analysis of the iris trial, which showed that pioglitazone 
reduced the risk for a composite outcome of stroke on myocardial infarction 
among non‐diabetic patients with insulin resistant and a recent stroke or 
transient ischemic attack. Now, the current planned secondary analysis used 
updated American Heart Association 2013 consensus criteria for ischemic stroke 
to examine the effect of pioglitazone on stroke outcomes. The study found that 
pioglitazone reduced the risk by 25% by five years, with absolute rates of 8% 
with pioglitazone versus 10.7% with placebo. Pioglitazone reduced the risk for 
ischemic strokes, but had no effect on the risk of hemorrhagic events. These 
findings add to the evidence that pioglitazone may be a potent therapy for 
vascular disease risk reduction and may help inform shared decision making by 
providers and patients for the use of pioglitazone after ischemic stroke or 
transient ischemic attack.  
  Well, that ends it for our summaries. Now for a feature discussion. 
  The cardiac troponins have really revolutionized cardiology. We use them in of 
course the diagnosis of myocardial infarction and in fact the recent European 
Society of Cardiology recommendations say that the rapid zero and one hour 
triage algorithm for rule in or rule out of non STEMI should use high sensitivity 
troponins and interestingly irrespective of renal function. Now this latter point 
has caused some confusion, some questions, since we all know that patients 
with chronic kidney disease frequently have higher or increased levels of cardiac 
troponins, especially since we now can detect them with the high sensitivity 
essays. And this is even in the absence of an acute coronary syndrome.  
  Well, this week's journal contains two papers that address this topic so well. 
And I am delighted to have with us the corresponding author of the first paper, 
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Dr. Christian Mueller from University Hospital Basel in Switzerland and the 
author of the second paper, Dr. Nicholas Mills from University of Edinburgh in 
Scotland. For the more, we have Dr. Torbjorn Omland, associate editor from 
University of Oslo in Norway.  
  Lot's to talk about. Christian, could I start with you? Could you say in your own 
words the rationale for looking at this vulnerable population and then perhaps 
describe what you did in your study? 
Dr. Christian Mueller:  I'm very thankful that Circulation shed a lot of light on the population of 
patients with renal dysfunction, because both as a clinician and as a researcher, 
I'm definitely convinced that they merit a lot of our attention for several 
reasons. 
  So first, it's important to be aware that the incidents of acute myocardial 
infarction among patients presenting with acute chest pain is much higher in 
patients with renal dysfunction, as compared to patients with normal renal 
function. And second, atypical clinical presentations also are more frequent in 
patients with renal dysfunction. Then possibly third, the ECG of course also a 
mandatory tool in our assessment is more often showing unspecific signs that 
may mimic or obscure the presence of myocardial infarctions and most of them 
are related to left ventricular hypertrophy. And in addition, patients with renal 
dysfunction are more prone to adverse events, both related to cardiovascular 
medication. For example, anticoagulation as well as our cardiovascular 
procedures, including PCI. Now again, as both papers have a strong focus on 
troponin, also cardiac troponin is a bit more difficult to interpret in patients with 
renal dysfunction related to exactly as you mentioned chronic elevations of 
cardiac troponin, TNI related to chronic cardiovascular disease.  
  And I think that's so important to stress, any troponin signal in a patient with 
renal dysfunction is real and should not be incorrectly attributed to just a 
problem of impaired secretion by the kidneys. 
Dr. Carolyn Lam:  So definitely an even greater need to diagnose myocardial infarction accurately 
in this very high risk population. So tell us what you did. 
Dr. Christian Mueller:  We assessed this challenging sub group within the APACE study. So APACE is a 
large international prospective diagnostic study that is run in five countries with 
12 centers. And we actually enroll consecutive patients presenting with 
suspected myocardial infarction. And then all patients get a very detailed 
workup and then adjudicated final diagnosis. And the adjudicated file diagnosis 
is done by two independent cardiologists and is based on two enormous 
extensive sets of data. The clinical data set that has been obtained at the local 
site and of course includes cardiac imaging and standard troponin testing, ECG 
data.  
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  In the second set of data that includes the study specific data sets, including 
serial measurements with high sensitivity carry troponin essay and a lot of 
details characterization of patients and patient follow up. So this is the 
reference standard against which the one hour algorithm the European Society 
of Cardiology evaluated. And the one hour algorithm has been derived and 
previously validated in overall population. Mainly patients with normal renal 
function. And so we tried to evaluate the performance of this predefined 
algorithm specifically in patients with renal dysfunctions.  
  So among a bit more than 3,000 patients, the prevalence of patients with renal 
dysfunction was 15%. So we had about 500 patients with renal dysfunction. And 
the interesting finding from our work is that first the prevalence of N‐STEMI was 
nearly threefold in patients with renal dysfunction as compared to patients with 
normal renal function. And, fortunately the rule out part of the algorithm 
regarding sensitivity still works very well. It is, however, the efficacy of rule out 
that is lower in patients with renal dysfunction, simply because fewer patients 
really have very low troponin concentration and are therefore ineligible for rule 
out. 
  However, as a clinician, the main concern with troponin and renal dysfunction is 
the rule in part, and specificity. And as you would think, specificity of the one 
hour algorithm was in fact significantly lower in patients with renal dysfunction. 
It was still appropriate for therapeutic consequences, but it was lower as 
compared to patients with normal renal function, so the specificity was 89% in 
patients with renal dysfunction, as compared to 96.5% in normal renal function. 
  So the overall efficacy of the algorithm was lower in patients with renal 
dysfunction, however then when trying to create and derive optimized cut off 
levels, so all cut off levels optimized for use in renal dysfunction, we didn't really 
find alternative cut offs that would do a much better job than the official cut off 
levels recommended in the guidelines. So our conclusion is that in patients with 
renal dysfunction, the safety of the one hour algorithm still is very high, 
however the specificity of rule in and overall efficacy are decreased. 
Dr. Carolyn Lam:  Right. That's beautifully summarized. And also that different cut offs didn't 
really help to increase the efficacy of this algorithm. And just to clarify to our 
listeners, I believe you defined renal dysfunction as an estimated GFR of less 
than 60, which is so beautiful because it's perfectly consistent with the second 
paper. 
  Nick, could you please tell us about your study and your take home messages as 
well. 
Dr. Nicholas Mills:  So high stakes is our clinical trial that we're conducting across hospitals in 
Scotland to evaluate the best way to use high levels of cardiac troponin in 
clinical practice. One of the areas of uncertainty is whether these assets really 
add any additional value for patients with chronic kidney disease, where 
troponin concentrations tend to be higher. And the premise of a high sensitive 
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test is that we can measure lower concentrations and improve the sensitivity. 
But is this just going to create uncertainty for clinicians?  
  So we evaluated 5,000 consecutive patients for performance of high sensitivity 
cardiac to put in testing. And those with and without renal impairment. And 
based upon what Christian, we identified that patients with renal impairment 
are less likely to have very low concentrations, but that you can rule out 
myocardial infarction safely in patients with renal impairment. And similarly that 
those with renal impairment are more likely to have an abnormal troponin 
concentration at presentation. Around about 40% of all patients have troponins 
above the upper reference limit. And whilst the specificity for myocardial 
infarction is lower, type one myocardial infarction or myocardial infarction due 
to plaque rupture or cardiac thrombosis remains the most common diagnosis in 
this group. 
  Finally we looked at one year outcomes. And this is really critical. Because we 
found that patients with renal impairment were two to threefold more likely to 
die from cardiovascular disease one year following their presentation than 
those without renal impairment. And I think that my general experience during 
these tests in clinical practice is that troponin elevations in patients with kidney 
disease are often ignored and there's a concern about what they mean, and 
therefore these patients don't get access to the fantastic treatments we have 
for coronary heart disease. So our take home message is that high sets of 
troponin testing in patients with renal disease does have value, it's useful for 
identifying low risk patients although there are fewer of them, and it performs 
well as a diagnostic test, highlighting in particular a group of patients that really 
have poor clinical outcomes. 
  As a cardiological community, we need to do better. 
Dr. Carolyn Lam:  What I really love about both or your papers is the consistency in the messages. 
Torbjorn, I want to bring you in on this. You managed both papers. Such a lovely 
pair of papers that we're so proud to be publishing and you had also invited an 
editorial by Dr. deFilippi and Seliger. Would you like to comment on your 
perspective and perhaps the clinical take home message to our audience? 
Dr. Torbjørn Omland:  Yes, I think this has been pointed very well out by both Christian and Nick. And I 
think it's worth recapitulating that renal dysfunction is a major problem that 
clinicians often try to explain by just lack of renal filtration. But that the closest 
probably are increased production and underlying cardiac disease. So in the 
editorial Dr. deFilippi Filippi and Dr. Seliger points also out in these things. 
Moreover they try to look forward and have made comments to recent studies 
that showed that in patients with renal dysfunction have different troponin 
fragments than patients with acute myocardial infarctions. 
Dr. Carolyn Lam:  I find that so fascinating. And it really, really relates to the field of heart failure 
and what we are also talking and thinking about with natriuretic peptides and 
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their different fragments and the possible different meanings. And how 
different essays maybe non specific for different fragments.  
  Christian, you think a lot about these things. I'm curious, what are your thoughts 
on this and areas of future work that are very urgent? 
Dr. Christian Mueller:  I think Torbjorn very nicely addressed this. So the current high sensitivity essays 
for T and I that we use in clinical practice, they are designed kind of to detect 
everything in blood that looks like troponin, either T or I, including various 
fragments. And I think it's a fantastic new avenue of research, trying to find out 
that the biochemical signatures can be further differentiated and exactly that 
perhaps different troponin fragments or tricordinate products more prominent 
in patients having ischemic injuries like treat myocardial infarction, as compared 
to for example other modes of injuries. So I think that's very nice hypothesis and 
some early data. But at least from my perspectives and to the best of my 
knowledge until now, the diagnostic algorithms that we have other ways to 
approach this in clinical practice. And so it's the higher the blood concentration 
in patients with acute chest pain, the more likely it's acute myocardial 
infarction. It's not any chronic disease and again the higher the change from 
presentation to one hour or two hours, the more likely it's acute as a dynamic 
disorder resulting in an acute increase in cardiac troponin, as compared to the 
chronic release patterns typically seen in patients with renal dysfunction. 
Dr. Carolyn Lam:  Yeah. That's just so fascinating. Nick, we sadly are running out of time, but I do 
want to give you the last word. The clinical take home message, once again. 
What do you think listeners should take home that may change their practice, 
after listening to this podcast? 
Dr. Nicholas Mills:  I think the key message for clinicians, is that in a patient with suspected acute 
coronary syndrome and has renal impairment and elevated troponin 
concentration, serial testing is mandatory to differentiate between those that 
have chronic myocardial injury due to subclinical heart disease and those that 
are having acute myocardial injury as a consequence of a presumed acute 
coronary syndrome. Field testing is critical to inform which treatment path and 
what investigations we recommend for our patients. 
Dr. Carolyn Lam:  Wonderful. And to take any elevations seriously, because this is a high risk 
population. 
  Well, audience you heard it right here on Circulation On The Run. I'm sure 
you've enjoyed this. I certainly have. Don't forget to tune in again next week. 
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Supplemental Methods 
Adjudication of the final diagnosis  
AMI was defined and cTn levels interpreted as recommended in current guidelines.1-4 In brief, 
AMI was diagnosed when there was evidence of myocardial necrosis with a significant rise 
and/or fall in a clinical setting consistent with myocardial ischemia. Patients with AMI were 
further subdivided into type 1 AMI (primary coronary events) and type 2 AMI (ischemia due to 
increased demand or decreased supply, for example tachyarrhythmia or hypertensive crisis).2, 
5  
 The adjudication of final diagnoses was performed centrally in the core lab (University 
Hospital Basel) for all patients incorporating levels of hs-cTnT (see test characteristics 
above). More specifically, two independent cardiologists not directly involved in patient care 
reviewed all available medical records (including patient history, physical examination, results 
of laboratory testing including hs-cTnT levels, radiologic testing, ECG, echocardiography, 
cardiac exercise test, lesion severity and morphology in coronary angiography, discharge 
summary) pertaining to the patient from the time of ED presentation to 90-day follow-up. Late 
samples were available for adjudication of final diagnosis in the vast majority of patients. In 
general, serial sampling was performed until at least 6h after presentation to the ED or onset 
of chest pain.2 Distributions of latest study blood samples according to time since ED 
presentation and time since chest pain onset are listed in supplemental Tables 2 and 3. It is 
important to highlight that in many patients additional (hs)-cTn measurements at late time 
points using the local (hs)-cTn assays obtained as part of routine clinical care were also 
available for the adjudication. In situations of diagnostic disagreement, cases were reviewed 
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and adjudicated in conjunction with a third cardiologist. While discharge diagnoses often were 
correct and in agreement with the final adjudicated diagnosis, there were also cases where 
those diagnoses needed to be revised, most often because more information became 
available from medical testing during early follow-up, and more rarely, because the discharge 
diagnosis was not in agreement with the Universal Definition of AMI.  
 The 99th percentile (14ng/L) was used as cutoff for myocardial necrosis. Absolute cTn 
changes were used to determine significant changes based on the diagnostic superiority of 
absolute over relative changes.6-11 Based on studies of the biological variation of cTn12-14 as 
well as on data from previous chest pain cohort studies,6, 15 a significant absolute change was 
defined as a rise or fall of at least 10ng/L within six hours, or, in an assumption of linearity, as 
an absolute change of 6ng/L within three hours. Predefined alternative diagnoses included 
“unstable angina” (UA), “Cardiac symptoms of origin other than coronary artery disease” and 
“non-cardiac chest pain”.  
Clinical Care: The (hs)-cTn assays and cutoff levels used for local clinical care 
Routine clinical care comprised five different cTn assays at the different hospitals and at the 
different recruitment periods. The cTn assays used clinically in most of the participating 
institutions changed during the study from a conventional cTn assay to the hs-cTnT assay. In 
order to take advantage of the higher sensitivity and higher overall diagnostic accuracy 
offered by the hs-cTnT assay, patients were adjudicated using the hs-cTnT values in all 
patients. In patients in whom clinically a conventional cTn assay was used, the conventional 
cTn values and the hs-cTnT values were available for the adjudication. In patients in whom 
clinically the hs-cTnT assay was used, only the hs-cTnT values were available for the 
adjudication. 
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The following conventional cTn assays were used:  
For the Roche cTnT 4th generation assay, the 10% CV level is 0.035ug/l. The 
laboratories of the participating sites reported only two decimals; therefore 0.04ug/l was used 
as a cutoff for myocardial necrosis. In order to fulfil the criteria of a significant change (30% of 
99th percentile or 10% CV level), a patient would e.g. need to have a level of <0.01ug/l at 
presentation and 0.04ug/l at 6h. A patient would also qualify if the first level is 0.02ug/l and 
the second 0.04ug/l. A patient would not fulfil the criteria if the first level is 0.03ug/l and the 
second is 0.04ug/l. If the first level is 0.04ug/l, the second level needs to be at least 0.06ug/l.  
For the Abbott Axsym cTnI ADV, the 10% CV level is 0.16ug/l. A patient having 
0.16ug/l at presentation would meet the criteria for significant change if the second was 
≥0.21ug/l. A patient having <0.12ug/l at presentation (limit of detection) would qualify if the 
second is >0.16ug/l.  
For the Beckmann Coulter Accu cTnI, the 10% CV level is 0.06ug/l. A patient having 
0.06ug/l at presentation would qualify if the second is ≥0.08ug/l. A patient having 0.05 at 
presentation would qualify if the second is 0.07ug/l, but not 0.06ug/l. A patient having 
undetectable cTnI (cTnI<0.01ug/l) at presentation would qualify if the second is ≥0.06ug/l. 
For the Siemens Dimension Vista s-cTnI, the 10% CV level is 40ng/L. The limit of 
detection is 15ng/L and the 99th percentile is 45ng/L. An absolute change of 20ng/L or more 
within 3-6h was considered significant. 
For Elecsys hs-cTnT measured clinically, the same change criteria were applied as for 
hs-cTnT measured from the study blood samples. 
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Supplemental Tables 
Supplemental Table 1: STARD Checklist for the Reporting of Studies of Diagnostic Accuracy 
Section & 
Topic 
No Item Reported on 
page # 
TITLE OR ABSTRACT 
 1 Identification as a study of diagnostic accuracy using at least one measure of accuracy (such 
as sensitivity, specificity, predictive values, or AUC) 
1, 2 
ABSTRACT 
 2 Structured summary of study design, methods, results, and conclusions  
(for specific guidance, see STARD for Abstracts) 
2-3 
INTRODUCTION 
 3 Scientific and clinical background, including the intended use and clinical role of the index test 5-6 
4 Study objectives and hypotheses 6 
METHODS 
Study design 5 Whether data collection was planned before the index test and reference standard  
were performed (prospective study) or after (retrospective study) 
7 
Participants 6 Eligibility criteria  7 
7 On what basis potentially eligible participants were identified  
(such as symptoms, results from previous tests, inclusion in registry) 
7 
8 Where and when potentially eligible participants were identified (setting, location and dates) 7 
 9 Whether participants formed a consecutive, random or convenience series 7 
Test methods 10a Index test, in sufficient detail to allow replication 9-10 
10b Reference standard, in sufficient detail to allow replication 8-9;Suppl. 2-4 
11 Rationale for choosing the reference standard (if alternatives exist) 8 
12a Definition of and rationale for test positivity cutoffs or result categories  
of the index test, distinguishing pre-specified from exploratory 
9-10 
12b Definition of and rationale for test positivity cutoffs or result categories  
of the reference standard, distinguishing pre-specified from exploratory 
Suppl. 2-4 
13a Whether clinical information and reference standard results were available  
to the performers/readers of the index test 
Suppl. 2-4 
13b Whether clinical information and index test results were available  
to the assessors of the reference standard 
Suppl. 2-4 
Analysis 14 Methods for estimating or comparing measures of diagnostic accuracy 12-13 
15 How indeterminate index test or reference standard results were handled 7 
16 How missing data on the index test and reference standard were handled 7 
17 Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from 
exploratory 
n.a. 
18 Intended sample size and how it was determined n.a. 
RESULTS 
Participants 19 Flow of participants, using a diagram Suppl. Fig. S2 
20 Baseline demographic and clinical characteristics of participants Tab. 1 
21a Distribution of severity of disease in those with the target condition n.a. 
21b Distribution of alternative diagnoses in those without the target condition n.a. 
22 Time interval and any clinical interventions between index test and reference standard n.a. 
Test results 23 Cross tabulation of the index test results (or their distribution)  
by the results of the reference standard 
15-19 
24 Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals) 15-19 
25 Any adverse events from performing the index test or the reference standard n.a. 
DISCUSSION 
 26 Study limitations, including sources of potential bias, statistical uncertainty, and 
generalisability  
20-25 
27 Implications for practice, including the intended use and clinical role of the index test 20-25 
OTHER INFORMATION 
 28 Registration number and name of registry 3 
29 Where the full study protocol can be accessed 3 
30 Sources of funding and other support; role of funders 26 
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Supplemental Table 2: Latest hs-cTnT value available x hours after 
presentation. 
 All patients 
(n=3254) 
Normal renal 
function (n=2767) 
Renal dysfunction 
(n=487) 
n % n % n % 
≥0h after presentation 3254 100% 2767 100% 487 100% 
≥1h after presentation 3254 100% 2767 100% 487 100% 
≥2h after presentation 2976 91% 2506 91% 470 97% 
≥3h after presentation 2513 77% 2076 75% 437 90% 
≥4h after presentation 2037 63% 1637 59% 400 82% 
≥5h after presentation 1915 59% 1524 55% 391 80% 
≥6h after presentation 1837 56% 1454 53% 383 79% 
 
 
 
 
 
Supplemental Table 3: Latest hs-cTnT value available x hours after symptom 
onset. 
 All patients 
(n=3254) 
Normal renal 
function (n=2767) 
Renal dysfunction 
(n=487) 
n % n % n % 
≥0h after symptom onset 3254 100% 2767 100% 487 100% 
≥1h after symptom onset 3254 100% 2767 100% 487 100% 
≥2h after symptom onset 3250 100% 2763 100% 487 100% 
≥3h after symptom onset 3226 99% 2741 99% 485 100% 
≥4h after symptom onset 3152 97% 2672 97% 480 99% 
≥5h after symptom onset 2995 92% 2518 91% 477 98% 
≥6h after symptom onset 2884 89% 2379 86% 465 95% 
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Supplemental Table 4:  Baseline Characteristics of Patients in Dataset B 
  
Normal Renal 
Function 
Renal 
Dysunction* 
 
Renal Dysfunction (n=445) 
NSTEMI 
n=2504 n=445 p-value† Yes (n=143) No (n=302) p-value‡ 
Age – years 58 [47, 70] 79 [73, 84] <0.001 80 [75, 86] 78 [72, 83] 0.003 
Male gender 1755 (70) 259 (58) <0.001 87 (61) 172 (57) 0.438 
Risk factors       
Hypertension 1406 (56) 402 (90) <0.001 132 (92) 270 (89) 0.333 
Hypercholesterolemia 1138 (45) 311 (70) <0.001 108 (76) 203 (67) 0.074 
Diabetes mellitus 398 (16) 125 (28) <0.001 49 (34) 76 (25) 0.046 
Current smoking 699 (28) 9 (9) <0.001 17 (12) 22 (7) 0.109 
History of smoking 916 (37) 205 (46) <0.001 67 (47) 138 (46) 0.819 
History       
Coronary artery disease 737 (29) 256 (58) <0.001 96 (67) 160 (53) 0.005 
Previous myocardial infarction 518 (21) 184 (41) <0.001 76 (53) 108 (36) 0.001 
Previous revascularization 626 (25) 189 (42) <0.001 69 (48) 120 (40) 0.090 
Peripheral artery disease 100 (4) 57 (13) <0.001 25 (17) 32 (11) 0.042 
Previous stroke 113 (5) 55 (12) <0.001 23 (16) 32 (11) 0.100 
Vital Status       
Heart rate – bpm   76 [66, 88] 75 [65, 91] 0.785 81 [69, 97] 73 [63, 88] 0.002 
Systolic blood pressure – mm Hg  142 [127, 158] 138 [121, 156] 0.001 137 [124, 157] 139 [121, 156] 0.983 
Diastolic blood pressure – mm Hg  82 [73, 92] 73 [64, 84] <0.001 73 [64, 83] 73 [64, 84] 0.831 
Body-mass index – kg/m² 26 [24, 30] 27 [24, 30] 0.230 26 [23, 28] 27 [25, 31] <0.001 
Electrocardiographic findings       
Left bundle branch block 71 (3) 45 (19) <0.001 18 (13) 27 (9) 0.233 
ST-segment depression 174 (7) 66 (15) <0.001 36 (25) 30 (10) <0.001 
T-wave inversion 260 (10) 78 (18) <0.001 37 (26) 41 (14) 0.001 
Laboratory measurements       
      Serum creatinine – μmol/l 73 [63, 83] 118 [100, 139] <0.001 123 [105, 151] 116 [97, 134] 0.003 
      Estimated GFR – ml/min/1.73m2 93 [81, 105] 48 [37, 55] <0.001 45 [34, 52] 49 [40, 55] <0.001 
Early presenters (≤2 h after CPO) 92 (21) 650 (26) 0.018 32 (22) 60 (20) 0.541 
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Categorical variables are presented as numbers (%), continuous variables are presented as medians [quartile 1, 
quartile 3]. CPO = chest pain onset; GFR = glomerular filtration rate; NSTEMI = Non-ST-Segment-Elevation Myocardial 
Infarction . Continuous variables were compared with the Mann-Whitney-U test, and categorical variables using the 
Pearson χ2 test or Fisher’s exact test, as appropriate. *Renal dysfunction was diagnosed if the estimated GFR was 
<60mL/min/1.73m2 using the chronic kidney disease epidemiology collaboration (CKD-EPI) formula based on plasma 
creatinine levels obtained at presentation to the ED, age, sex and ethnicity. † for comparisons between patients with 
normal renal function and renal dysfunction. ‡ for comparisons between patients with and without acute myocardial 
infarction in the subset of patients with renal dysfunction. 
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Supplemental Table 5:  Baseline Characteristics of Patients in Dataset A and Dataset B 
  
Dataset A Dataset B  
Renal Dysfunction* 
Dataset A  Dataset B  
n=3254 n=2949 p-value† n=487 n=445 p-value‡ 
Age – years 61 [49, 74] 62 [49, 74] 0.946 79 [73, 84] 79 [73, 84] 0.919 
Male gender 2208 (68) 2014 (68) 0.711 284 (58) 259 (58) 0.972 
Risk factors       
Hypertension 1993 (61) 1808 (61) 0.961 347 (71) 402 (90) 0.921 
Hypercholesterolemia 1605 (49) 1449 (49) 0.882 347 (71) 311 (70) 0.648 
Diabetes mellitus 570 (18) 523 (18) 0.822 136 (28) 125 (28) 0.956 
Current smoking 814 (29) 738 (25) 0.993 44 (9) 9 (9) 0.885 
History of smoking 1224 (38) 1121 (38) 0.747 223 (46) 205 (46) 0.932 
History       
Coronary artery disease 1091 (34) 993 (34) 0.904 280 (57) 256 (58) 0.992 
Previous myocardial infarction 780 (24) 702 (24) 0.878 204 (42) 184 (41) 0.867 
Previous revascularization 904 (28) 815 (28) 0.899 209 (43) 189 (42) 0.891 
Peripheral artery disease 172 (5) 157 (5) 0.947 62 (13) 57 (13) 0.972 
Previous stroke 181 (6) 168 (6) 0.818 58 (12) 55 (12) 0.834 
Vital Status       
Heart rate – bpm   76 [66, 89] 76 [66, 89] 0.940 75 [64, 91] 75 [65, 91] 0.806 
Systolic blood pressure – mm Hg  141 [126, 158] 141 [126, 157] 0.874 138 [121, 156] 138 [121, 156] 0.960 
Diastolic blood pressure – mm Hg  81 [71, 91] 81 [71, 91] 0.821 73 [64, 84] 73 [64, 84] 0.955 
Body-mass index – kg/m² 26 [24, 30] 27 [24, 30] 0.672 27 [24, 30] 27 [24, 30] 0.790 
Electrocardiographic findings       
Left bundle branch block 124 (4) 116 (4) 0.802 48 (10) 45 (19) 0.896 
ST-segment depression 166 (8) 140 (8) 0.959 74 (15) 66 (15) 0.877 
T-wave inversion 372 (8) 338 (11) 0.971 84 (17) 78 (18) 0.910 
Laboratory measurements       
      Serum creatinine – μmol/l 76 [65, 89] 76 [65, 90] 0.943 118 [101, 140] 118 [100, 139] 0.841 
      Estimated GFR – ml/min/1.73m2 89 [72, 102] 89 [72, 102] 0.779 48 [37, 55] 48 [37, 55] 0.940 
Early presenters (≤2h after CPO) 828 (25) 742 (25) 0.797 97 (20) 92 (21) 0.774 
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Categorical variables are presented as numbers (%), continuous variables are presented as medians [quartile 1, 
quartile 3]. CPO = chest pain onset; GFR = glomerular filtration rate. Continuous variables were compared with the 
Mann-Whitney-U test, and categorical variables using the Pearson χ2 test or Fisher’s exact test, as appropriate. 
*Renal dysfunction was diagnosed if the estimated GFR was <60mL/min/1.73m2 using the chronic kidney disease 
epidemiology collaboration (CKD-EPI) formula based on plasma creatinine levels obtained at presentation to the ED, 
age, sex and ethnicity. † for comparisons between patients in Dataset A and Dataset B. ‡ for comparisons between 
patients with renal dysfunction in Dataset A and B.  
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CAD = coronary artery disease. * e.g. tachyarrhythmia, Tako-Tsubo cardiomyopathy, heart failure or myocarditis. † X2-
test for comparison of proportions in patients with normal renal function and renal dysfunction.  
 
 
 
Supplemental Table 6:  Distribution of the adjudicated final diagnoses. 
  
All patients Normal Renal Function Renal Dysfunction 
p-value† 
n=3254 n=2767 n=487 
Non-ST-Segment-Elevation 
Myocardial Infarction 
515 (16) 364 (13) 151 (31) <0.001 
- Type 1 446 (14) 329 (12) 117 (24) <0.001 
- Type 2 68 (2) 35 (1) 33 (7) <0.001 
Unstable Angina 317 (10) 253 (9) 64 (13) 0.006 
Cardiac cause, but not CAD* 491 (15) 396 (14) 95 (20) 0.001 
Non-cardiac cause 1797 (55) 1634 (59) 163 (33) 0.001 
Unknown 134 (4) 120 (4) 14 (3) 0.134 
12 
 
 
Supplemental Table 7: Patients with an adjudicated diagnosis of Non-ST-Segment-Elevation Myocardial Infarction missed 
by the 0/1h-algorithm using high-sensitivity cardiac troponin T (n=3 of 3254), none of them with renal dysfunction. 
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0h 1h 2h 
3-
12h 
0h 1h 2h 
3-
12h 
#1 no 71 74 female 1 1 no 10 12 17 17* 3.1 7.3 9.5 10.8* no unstable Angina yes no 
#2 no 89 67 female 1 1 no 6 7 12 12* 4 8 18*  no NSTEMI yes no 
#3 no 64 86 female 17 3 yes 8* 7 7 7 27 24 27 29* no NSTEMI no no 
 
CAD = coronary artery disease; CABG = coronary artery bypass grafting; ECG = electrocardiography; 
eGFR=estimated glomerular filtration rate using CKD-EPI formula; hs-cTn = high-sensitivity cardiac troponin; PCI = 
percutaneous coronary intervention. * indicates peak level during serial sampling. 
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Supplemental Table 8: Patients with an adjudicated diagnosis of Non-ST-Segment-Elevation Myocardial Infarction  missed 
by the 0/1h-algorithm using high-sensitivity cardiac troponin I (n=7 of 2949), two of them with renal dysfunction. 
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0h 1h 2h 3-
12h 
0h 1h 2h 3-
12h 
#1 yes 56 75 male 5 4 yes 39* 35   4.5 5.3*   no 
cardiac 
arrhythmia 
no no 
#2 yes 31 93 female 9 9 yes 41* 38  34 3.6* 2.4   no 
unknown chest 
pain 
no no 
#3 no 69 77 male 5 4 no 55* 53  45 4.7 4.8  5.1* no 
unknown chest 
pain 
no no 
#4 no 95 73 male 4 4 yes 33* 32 28  3.4 3.9*   no 
unknown chest 
pain 
no no 
#5 no 72 75 male 1 1 yes 6 11 15*  2.9 4.8 8.8*  no unstable angina no no 
#6 no 104 52 male 4 4 no 43* 37 35 28 2.8* 2.8 2.5  no 
unknown chest 
pain 
no no 
#7 no 69 79 female 1 1 yes 18 19 22 24* 3.9 5.8 7.0*  yes 
cardiac 
arrhythmia 
no no 
CAD = coronary artery disease; CABG = coronary artery bypass grafting; ECG = electrocardiography; 
eGFR=estimated glomerular filtration rate using CKD-EPI formula; hs-cTn = high-sensitivity cardiac troponin; PCI = 
percutaneous coronary intervention. * indicates peak hs-cTn level during serial sampling. 
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Supplemental Table 9: Performance of the European Society of Cardiology 0/1h-
algorithm in patients with renal dysfunction and normal renal function presenting 
within 2 hours after chest pain onset to the emergency department. 
Using high-sensitivity cardiac troponin T 
 
Renal dysfunction  
- n=97 
Normal renal 
function - n=731 
p-value* 
Prevalence of NSTEMI 36 13 <0.001 
Sensitivity of rule-out 100.0 (90.0-100.0) 98.0 (92.8-99.8) 1.0 
NPV of rule-out 100.0 (n.a.) 99.6 (98.5-99.9) 1.0 
Specificity of rule-in 90.3 (80.1-96.4) 95.7 (93.9-97.2) 0.056 
PPV of rule-in 82.7 (69.0-91.3) 73.5 (65.4-80.3) 0.267 
Proportion ruled-out 19.6 (11.6-28.4) 70.3 (66.8-73.6) <0.001 
  - based on 0h-sample only - - - 
  - based on 0h/1h-samples 19.6 (11.6-28.4) 70.3 (66.8-73.6) <0.001 
Proportion ruled-in 36.1 (26.6-45.2) 14.0 (11.5-16.5) <0.001 
  - based on 0h-sample only 23.7 (15.2-32.7) 4.5 (3.1-6.1) <0.001 
  - based on 1h-change 12.4 (6.2-19.2) 9.4 (7.5-11.7) 0.361 
Overall Efficacy 55.7 (46.0-64.9) 84.3 (81.4-86.8) <0.001 
Prevalence of NSTEMI in 
the observational group 
14 (4-26) 18 (11-25) 0.522 
Using high-sensitivity cardiac troponin I 
 
Renal dysfunction  
- n=92 
Normal renal 
function - n=650 
p-value* 
Prevalence of NSTEMI  35 14 <0.001 
Sensitivity of rule-out 100.0 (89.1-100.0) 97.7 (92.0-99.7) 1.0 
NPV of rule-out 100.0 (n.a.) 99.5 (98.1-99.9) 1.0 
Specificity of rule-in 88.3 (77.4-95.2) 92.5 (90.0-94.6) 0.252 
PPV of rule-in 76.7 (61.3-87.2) 63.8 (56.5-70.5) 0.185 
Proportion ruled-out 23.9 (15.4-32.6) 61.4 (57.6-65.1) <0.001 
  - based on 0h-sample only - - - 
  - based on 0/1h-samples 23.9 (15.4-32.6) 61.4 (57.6-65.1) <0.001 
Proportion ruled-in 32.6 (23.4-43.3) 17.8 (15.0-20.7) 0.001 
  - based on 0h-sample only 17.4 (9.6-25.5) 8.8 (6.7-10.9) 0.009 
  - based on 1h-change 15.2 (8.1-23.4) 9.1 (6.9-11.3) 0.064 
Overall Efficacy 55.4 (45.3-65.9) 82.6 (79.6-85.5) <0.001 
Prevalence of NSTEMI in 
the observational group 
23 (10-36) 9 (4-14) 0.020 
 
Numbers represent percentage (95% confidence interval). * performances measures in 
patients with renal dysfunction and normal renal function were compared using χ2 or Fisher’s 
exact test. n.a.= not applicable; NPV = negative predictive value; NSTEMI = Non-ST-
Segment-Elevation Myocardial Infarction, PPV = positive predictive value.  
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Supplemental Table 10: Performance of the European Society of Cardiology 0/1h-
algorithm in patients with renal dysfunction and presence or absence of pre-existing kidney 
disease. 
Using high-sensitivity cardiac troponin T 
 
Pre-existing kidney disease p-
value* present - n=276 absent - n=211 
Prevalence of NSTEMI 37 24 0.002 
Sensitivity of rule-out 100.0 (96.4-100.0) 100.0 (92.9-100.0) 1.0 
NPV of rule-out 100.0 (n.a.) 100.0 (n.a.) 1.0 
Specificity of rule-in 88.0 (82.2-92.4) 89.4 (83.6-93.7) 0.677 
PPV of rule-in 79.8 (72.4-85.6) 70.7 (60.2-79.4) 0.136 
Proportion ruled-out 10.9 (7.3-14.9) 27.5 (21.5-33.6) <0.001 
  - based on 0h-sample only 0.4 (0.0-1.2) 2.8 (0.9-5.2) 0.023 
  - based on 0h/1h-samples 10.5 (6.9-14.4) 24.6 (19.2-30.8) <0.001 
Proportion ruled-in 37.7 (32.0-43.0) 27.5 (21.7-33.9) 0.018 
  - based on 0h-sample only 29.3 (23.8-34.9) 21.3 (15.9-27.4) 0.364 
  - based on 1h-change 8.3 (5.1-11.8) 6.2 (3.1-9.9) 0.160 
Overall Efficacy 48.6 (42.4-54.1) 55.0 (47.9-61.6) 0.160 
Prevalence of NSTEMI in the 
observational group 
13 (7-19) 10 (4-16) 0.447 
Using high-sensitivity cardiac troponin I 
 
Pre-existing kidney disease p-
value* present - n=251 absent - n=194 
Prevalence of NSTEMI  38 24 0.002 
Sensitivity of rule-out 100.0 (96.2-100.0) 95.7 (85.5-99.5) 0.106 
NPV of rule-out 100.0 (n.a.) 95.7 (84.7-98.9) 0.510 
Specificity of rule-in 81.3 (74.3-87.1) 87.8 (81.3-92.6) 0.122 
PPV of rule-in 72.4 (65.0-78.7) 67.9 (57.3-76.9) 0.549 
Proportion ruled-out 12.7 (8.8-17.2) 23.7 (18.0-29.8) 0.003 
  - based on 0h-sample only 0.4 (0.0-1.3) 2.6 (0.5-5.1) 0.048 
  - based on 0h/1h-samples 12.4 (8.5-16.5) 21.1 (15.6-27.0I 0.013 
Proportion ruled-in 41.8 (36.0-47.6) 28.9 (22.5-35.7) 0.005 
  - based on 0h-sample only 30.3 (25.1-36.3) 22.7 (16.8-28.8) 0.073 
  - based on 1h-change 11.6 (7.8-15.6) 6.2 (2.9-9.6) 0.052 
Overall Efficacy 54.6 (48.2-60.8) 52.1 (44.8-58.9) 0.597 
Prevalence of NSTEMI in the 
observational group 
18 (11-24) 8 (3-14) 0.033 
 
Numbers represent percentage (95% confidence interval). * performances measures in 
patients with and without pre-existing kidney disease were compared using χ2 or Fisher’s 
exact test. n.a.= not applicable; NPV = negative predictive value; NSTEMI = Non-ST-
Segment-Elevation Myocardial Infarction, PPV = positive predictive value. 
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Supplemental Table 11: Performance of the European Society of Cardiology 0/1h-algorithm 
in women and men with renal dysfunction. 
Using high-sensitivity cardiac troponin T 
 Women - n=203 Men - n=284 p-value* 
Prevalence of NSTEMI 29 33 0.326 
Sensitivity of rule-out 100.0 (93.8-100.0) 100.0 (96.1-100.0) 1.0 
NPV of rule-out 100.0 (n.a.) 100.0 (n.a.) 1.0 
Specificity of rule-in 91.0 (85.2-95.1) 86.9 (81.3-91.4) 0.238 
PPV of rule-in 80.6 (71.1-87.5) 73.7 (65.6-80.4) 0.310 
Proportion ruled-out 28.1 (22.1-34.2) 10.9 (7.4-14.9) <0.001 
  - based on 0h-sample only 3.0 (0.9-5.7) 0.4 (0.0-1.2) 0.017 
  - based on 0h/1h-samples 25.1 (19.3-31.1) 10.6 (7.1-14.4) <0.001 
Proportion ruled-in 33.0 (26.9-39.9) 33.5 (27.7-38.6) 0.918 
  - based on 0h-sample only 22.2 (16.7-28.8) 28.5 (23.3-33.5) 0.114 
  - based on 1h-change 10.8 (6.8-15.7) 4.9 (2.7-7.4) 0.014 
Overall Efficacy 61.1 (54.7-67.5) 44.4 (38.5-50.4) <0.001 
Prevalence of NSTEMI in the 
observational group 
5 (0-10) 15 (9-21) 0.030 
Using high-sensitivity cardiac troponin I 
 Women - n=186 Men - n=259 p-value* 
Prevalence of NSTEMI  30 34 0.438 
Sensitivity of rule-out 98.2 (90.5-100.0) 98.9 (93.8-100.0) 1.0 
NPV of rule-out 97.7 (85.9-99.7) 97.1 (82.1-99.6) 1.0 
Specificity of rule-in 88.5 (75.9-94.8) 81.4 (74.8-86.9) 0.094 
PPV of rule-in 76.6 (66.8-84.2) 67.0 (59.2-74.0) 0.193 
Proportion ruled-out 23.7 (17.5-29.7) 13.1 (9.1-17.2) 0.004 
  - based on 0h-sample only 1.6 (0.0-3.6) 1.2 (0.0-2.6) 0.682 
  - based on 0h/1h-samples 22.0 (15.9-28.2) 12.0 (8.1-15.8) 0.004 
Proportion ruled-in 34.4 (27.8-41.4) 37.5 (31.6-43.2) 0.510 
  - based on 0h-sample only 25.8 (19.9-32.2) 27.8 (21.8-33.2) 0.640 
  - based on 1h-change 8.6 (5.0-12.8) 9.7 (5.9-13.6) 0.706 
Overall Efficacy 58.1 (50.6-65.0) 50.2 (43.9-56.0) 0.101 
Prevalence of NSTEMI in the 
observational group 
8 (2-15) 16 (11-23) 0.075 
 
Numbers represent percentage (95% confidence interval). * performances measures in male 
and femal patients were compared using χ2 or Fisher’s exact test. n.a.= not applicable; NPV 
= negative predictive value; NSTEMI = Non-ST-Segment-Elevation Myocardial Infarction, 
PPV = positive predictive value.  
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Supplemental Table 12: Performance of the European Society of Cardiology 0/1h-
algorithm in patients with renal dysfunction and normal renal function after exclusion of 
patients that were part of the original derivation cohorts. 
Using high-sensitivity cardiac troponin T 
 
Renal dysfunction  
- n=418 
Normal renal 
function - n=2428 
p-value* 
Prevalence of NSTEMI 31 13 <0.001 
Sensitivity of rule-out 100.0 (97.2-100.0) 99.0 (97.2-99.8) 0.559 
NPV of rule-out 100.0 (n.a.) 99.8 (99.5-99.9) 1.0 
Specificity of rule-in 90.3 (86.3-93.4) 96.6 (95.8-97.4) <0.001 
PPV of rule-in 78.6 (71.9-84.1) 77.2 (72.7-81.1) 0.738 
Proportion ruled-out 18.7 (15.2-22.4) 68.5 (66.7-70.2) <0.001 
  - based on 0h-sample only 1.4 (0.5-2.7) 18.0 (16.4-19.5) <0.001 
  - based on 0h/1h-samples 17.2 (1.9-20.9) 50.5 (48.7-52.3) <0.001 
Proportion ruled-in 31.3 (26.9-35.7) 12.8 (11.5-14.2) <0.001 
  - based on 0h-sample only 23.9 (19.8-28.0) 7.7 (6.7-8.8) <0.001 
  - based on 1h-change 7.4 (5.1-10.1) 5.1 (4.2-6.0) 0.050 
Overall Efficacy 50.0 (45-55.0) 81.3 (79.8-82.9) <0.001 
Prevalence of NSTEMI in the 
observational group 
13 (8-18) 16 (13-19) 0.359 
Using high-sensitivity cardiac troponin I 
 
Renal dysfunction - 
n=313 
Normal renal 
function - n=1740 
p-value* 
Prevalence of NSTEMI  28 13 <0.001 
Sensitivity of rule-out 100.0 (95.9-100.0) 99.1 (96.8-99.9) 1.0 
NPV of rule-out 100.0 (n.a.) 99.8 (99.2-100.0) 1.0 
Specificity of rule-in 84.0 (78.5-88.5) 90.5 (88.9-91.9) 0.003 
PPV of rule-in 65.7 (58.2-72.5) 57.9 (53.9-61.8) 0.153 
Proportion ruled-out 17.6 (13.5-21.8) 55.6 (54.4-59.0) <0.001 
  - based on 0h-sample only 1.3 (0.3-2.5) 11.3 (9.7-12.8) <0.001 
  - based on 0h/1h-samples 16.3 (12.2-20.5) 45.3 (43.2-47.6) <0.001 
Proportion ruled-in 33.5 (28.4-38.7) 19.7 (17.7-21.5) <0.001 
  - based on 0h-sample only 24.3 (19.8-29.2) 13.8 (12.2-15.4) <0.001 
  - based on 1h-change 9.3 (6.0-12.5) 5.9 (4.8-7.0) 0.023 
Overall Efficacy 52.1 (46.8-57.4) 76.2 (74.3-78.2) <0.001 
Prevalence of NSTEMI in the 
observational group 
12 (7-18) 6 (4-8) 0.013 
 
408 patients of dataset A were part of the original derivation cohort of the hs-cTnT 0/1h-algorithm and  
896 patients of dataset B were part of the original derivation cohort of the hs-cTnI 0/1h-algorithm. 
Numbers represent percentage (95% confidence interval). * performances measures in patients with 
renal dysfunction and normal renal function were compared using χ2 or Fisher’s exact test. n.a. = not 
applicable; NPV = negative predictive value; NSTEMI = Non-ST-Segment-Elevation Myocardial 
Infarction, PPV = positive predictive value.  
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Supplemental Table 13: Diagnostic performance of multiple cutoff criteria combinations using high-sensitivity cardiac troponin T 
(based on 0-hour sample concentration and 1-hour change) for rapid rule-out and rule-in of Non-ST-Segment-Elevation 
Myocardial Infarction in patients with renal dysfunction. 
 Criteria Diagnostic Performance 
 Direct Rule-
out based 
on 0h-
sample OR 
Rule-out based on 0h- and 
1h- sample 
Rule-out Sensitivity 
(95% CI) 
Rule-out NPV 
(95% CI) 
Proportion Rule-
out (95% CI) 
Proportion 
direct Rule-out 
based on 0h-
sample only 
 (95% CI) 0h hs-cTnT 
0h hs-
cTnT 
AND 
1h-change 
hs-cTnT 
R
u
le
-o
u
t 
s
tr
a
te
g
y
 
<5 ng/L OR 
<12 ng/L 
AND 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 18.1 (14.6-21.6) 1.4 (0.4-2.6) 
<4 ng/L 100.0 (97.6-100) 100.0 (n.a.) 18.1 (14.6-21.6) 1.4 (0.4-2.6) 
<14 ng/L 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 22.6 (18.8-26.7) 1.4 (0.4-2.6) 
<4 ng/L 99.3 (96.4-100) 99.1 (94.0-99.9) 23.0 (19.2-27.1) 1.4 (0.4-2.6) 
<16 ng/L 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 29.0 (25.1-33.1) 1.4 (0.4-2.6) 
<4 ng/L 99.3 (96.4-100) 99.3 (95.3-99.9) 29.4 (25.4-33.5) 1.4 (0.4-2.6) 
<18 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.8 (95.3-99.7) 33.5 (29.1-37.8) 1.4 (0.4-2.6) 
<4 ng/L 97.4 (93.4-99.3) 97.6 (93.9-99.1) 34.1 (29.7-38.4) 1.4 (0.4-2.6) 
<20 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.9 (95.7-99.7) 37.0 (32.7-41.3) 1.4 (0.4-2.6) 
<4 ng/L 96.7 (92.4-98.9) 97.3 (93.8-98.9) 38.0 (33.7-42.5) 1.4 (0.4-2.6) 
<6 ng/L OR 
<12 ng/L 
AND 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 18.1 (14.6-21.6) 1.6 (0.6-2.9) 
<4 ng/L 100.0 (97.6-100) 100.0 (n.a.) 18.1 (14.6-21.6) 1.6 (0.6-2.9) 
<14 ng/L 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 22.6 (18.8-26.7) 1.6 (0.6-2.9) 
<4 ng/L 99.3 (96.4-100) 99.1 (94.0-99.9) 23.0 (19.2-27.1) 1.6 (0.6-2.9) 
<16 ng/L 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 29.0 (25.1-33.1) 1.6 (0.6-2.9) 
<4 ng/L 99.3 (96.4-100) 99.3 (95.3-99.9) 29.4 (25.4-33.5) 1.6 (0.6-2.9) 
<18 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.8 (95.3-99.7) 33.5 (29.1-37.8) 1.6 (0.6-2.9) 
<4 ng/L 97.4 (93.4-99.3) 97.6 (93.9-99.1) 34.1 (29.7-38.4) 1.6 (0.6-2.9) 
<20 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.9 (95.7-99.7) 37.0 (32.7-41.3) 1.6 (0.6-2.9) 
<4 ng/L 96.7 (92.4-98.9) 97.3 (93.8-98.9) 38.0 (33.7-42.5) 1.6 (0.6-2.9) 
<8 ng/L OR 
<12 ng/L 
AND 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 18.1 (14.6-21.6) 4.9 (3.1-7.0) 
<4 ng/L 100.0 (97.6-100) 100.0 (n.a.) 18.1 (14.6-21.6) 4.9 (3.1-7.0) 
<14 ng/L 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 22.6 (18.8-26.7) 4.9 (3.1-7.0) 
<4 ng/L 99.3 (96.4-100) 99.1 (94.0-99.9) 23.0 (19.2-27.1) 4.9 (3.1-7.0) 
<16 ng/L 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 29.0 (25.1-33.1) 4.9 (3.1-7.0) 
<4 ng/L 99.3 (96.4-100) 99.3 (95.3-99.9) 29.4 (25.4-33.5) 4.9 (3.1-7.0) 
<18 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.8 (95.3-99.7) 33.5 (29.1-37.8) 4.9 (3.1-7.0) 
<4 ng/L 97.4 (93.4-99.3) 97.6 (93.9-99.1) 34.1 (29.7-38.4) 4.9 (3.1-7.0) 
<20 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.9 (95.7-99.7) 37.0 (32.7-41.3) 4.9 (3.1-7.0) 
<4 ng/L 96.7 (92.4-98.9) 97.3 (93.8-98.9) 38.0 (33.7-42.5) 4.9 (3.1-7.0) 
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Supplemental Table 13 (continued): Diagnostic performance of multiple cutoff criteria combinations using high-sensitivity 
cardiac troponin T (based on 0-hour sample concentration and 1-hour change) for rapid rule-out and rule-in of Non-ST-
Segment-Elevation Myocardial Infarction in patients with renal dysfunction. 
 Criteria Diagnostic Performance 
R
u
le
-o
u
t 
s
tr
a
te
g
y
 
Direct Rule-
out based on 
0h-sample 
OR 
Rule-out based on 0h- and 
1h- sample Rule-out 
Sensitivity 
(95% CI) 
Rule-out NPV 
(95% CI) 
Proportion Rule-
out (95% CI) 
Proportion direct 
Rule-out based 
on 0h-sample 
only 
 (95% CI) 
0h hs-cTnT 
0h  
hs-cTnT 
AND 
1h-
change 
hs-cTnT 
<10 ng/L OR 
<12 ng/L 
AND 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 18.1 (14.6-21.6) 9.0 (6.5-11.6) 
<4 ng/L 100.0 (97.6-100) 100.0 (n.a.) 18.1 (14.6-21.6) 9.0 (6.5-11.6) 
<14 ng/L 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 22.6 (18.8-26.7) 9.0 (6.5-11.6) 
<4 ng/L 99.3 (96.4-100) 99.1 (94.0-99.9) 23.0 (19.2-27.1) 9.0 (6.5-11.6) 
<16 ng/L 
<3 ng/L 100.0 (97.6-100) 100 (n.a.) 29.0 (25.1-33.1) 9.0 (6.5-11.6) 
<4 ng/L 99.3 (96.4-100) 99.3 (95.3-99.9) 29.4 (25.4-33.5) 9.0 (6.5-11.6) 
<18 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.8 (95.3-99.7) 33.5 (29.1-37.8) 9.0 (6.5-11.6) 
<4 ng/L 97.4 (93.4-99.3) 97.6 (93.9-99.1) 34.1 (29.7-38.4) 9.0 (6.5-11.6) 
<20 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.9 (95.7-99.7) 37.0 (32.7-41.3) 9.0 (6.5-11.6) 
<4 ng/L 96.7 (92.4-98.9) 97.3 (93.8-98.9) 38.0 (33.7-42.5) 9.0 (6.5-11.6) 
<12 ng/L OR 
<14 ng/L 
AND 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 22.6 (18.8-26.7) 12.3 (9.5-15.3) 
<4 ng/L 99.3 (96.4-100) 99.1 (94.0-99.9) 23.0 (19.2-27.1) 12.3 (9.5-15.3) 
<16 ng/L 
<3 ng/L 100.0 (97.6-100) 100.0 (n.a.) 29.0 (25.1-33.1) 12.3 (9.5-15.3) 
<4 ng/L 99.3 (96.4-100) 99.3 (95.3-99.9) 29.4 (25.4-33.5) 12.3 (9.5-15.3) 
<18 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.8 (95.3-99.7) 33.5 (29.1-37.8) 12.3 (9.5-15.3) 
<4 ng/L 97.4 (93.4-99.3) 97.6 (93.9-99.1) 34.1 (29.7-38.4) 12.3 (9.5-15.3) 
<20 ng/L 
<3 ng/L 98.7 (95.3-99.8) 98.9 (95.7-99.7) 37.0 (32.7-41.3) 12.3 (9.5-15.3) 
<4 ng/L 96.7 (92.4-98.9) 97.3 (93.8-98.9) 38.0 (33.7-42.5) 12.3 (12.3-18.8) 
<14 ng/L OR 
<16 ng/L 
AND 
<3 ng/L 99.3 (96.4-100) 99.3 (95.3-99.9) 29.2 (25.3-33.2) 15.4 (12.3-18.8) 
<4 ng/L 99.3 (96.4-100) 99.3 (95.3-99.9) 29.4 (25.4-33.5) 15.4 (12.3-18.8) 
<18 ng/L 
<3 ng/L 98.0 (94.3-99.6) 98.2 (94.6-99.4) 33.7 (29.4-38.2) 15.4 (12.3-18.8) 
<4 ng/L 97.4 (93.4-99.3) 97.6 (93.9-99.1) 34.1 (29.7-38.4) 15.4 (12.3-18.8) 
<20 ng/L 
<3 ng/L 98.0 (94.3-99.6) 98.3 (95.1-99.5) 37.2 (32.9-41.5) 15.4 (12.3-18.8) 
<4 ng/L 96.7 (92.4-98.9) 97.3 (93.8-98.9) 38.0 (33.7-42.5) 15.4 (12.3-18.8) 
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Supplemental Table 13 (continued): Diagnostic performance of multiple cutoff criteria combinations using high-sensitivity 
cardiac troponin T (based on 0-hour sample concentration and 1-hour change) for rapid rule-out and rule-in of Non-ST-
Segment-Elevation Myocardial Infarction in patients with renal dysfunction. 
 Criteria Diagnostic Performance 
 Direct Rule-in 
based on 0h-
sample OR 
Rule-in based on 
1h-change 
Rule-in 
Specificity  
(95% CI) 
Rule-in PPV 
(95% CI) 
Proportion Rule-
in (95% CI) 
Proportion direct 
Rule-in based on 
0h-sample only 
 (95% CI) 0h hs-cTnT 
1h-change 
hs-cTnT 
R
u
le
-i
n
 s
tr
a
te
g
y
 
≥52 ng/L OR 
≥5 ng/L 88.7 (84.8-91.9) 76.5 (70.6-81.6) 33.3 (29.3-37.5) 25.9 (22.4-29.7) 
≥6 ng/L 89.9 (86.2-92.9) 78.2 (82.1-83.3) 32.0 (28.3-36.3) 25.9 (22.4-29.7) 
≥7 ng/L 89.9 (86.2-92.9) 77.6 (71.4-82.8) 31.2 (27.4-35.4) 25.9 (22.4-29.7) 
≥8 ng/L 89.9 (86.2-92.9) 77.3 (71.0-82.6) 30.8 (26.8-34.9) 25.9 (22.4-29.7) 
≥9 ng/L 89.9 (86.2-92.9) 77.0 (70.7-82.4) 30.4 (26.5-34.6) 25.9 (22.4-29.7) 
≥60 ng/L OR 
≥5 ng/L 90.5 (86.8-93.4) 78.2 (71.9-83.5) 30.2 (26.2-34.3) 19.7 (16.3-23.2) 
≥6 ng/L 92.0 (88.5-94.6) 80.6 (74.1-85.8) 28.5 (24.6-32.5) 19.7 (16.3-23.2) 
≥7 ng/L 92.0 (88.5-94.6) 80.0 (73.3-85.3) 27.7 (24.0-31.6) 19.7 (16.3-23.2) 
≥8 ng/L 92.6 (89.2-95.1) 80.8 (74.0-86.1) 26.7 (22.7-30.6) 19.7 (16.3-23.2) 
≥9 ng/L 92.6 (89.2-95.1) 80.2 (73.2-85.7) 25.9 (22.0-29.7) 19.7 (16.3-23.2) 
≥80 ng/L OR 
≥5 ng/L 92.6 (89.2-95.1) 81.5 (74.9-86.7) 27.7 (23.7-31.7) 15.2 (11.9-18.4) 
≥6 ng/L 94.4 (91.3-96.6) 84.9 (78.2-89.8) 25.9 (22.1-29.8) 15.2 (11.9-18.4) 
≥7 ng/L 94.4 (91.3-96.6) 84.3 (77.4-89.4) 24.8 (21.1-28.7) 15.2 (11.9-18.4) 
≥8 ng/L 94.9 (92.0-97.0) 85.2 (78.1-90.3) 23.6 (19.8-27.3) 15.2 (11.9-18.4) 
≥9 ng/L 94.9 (92.0-97.0) 84.7 (77.4-89.9) 22.8 (19.2-26.6) 15.2 (11.9-18.4) 
≥100 ng/L OR 
≥5 ng/L 93.8 (90.6-96.1) 83.7 (77.1-88.7) 26.5 (22.7-30.5) 11.3 (8.6-14.2) 
≥6 ng/L 95.5 (92.7-97.5) 87.4 (80.7-92.0) 24.4 (20.7-28.4) 11.3 (8.6-14.2) 
≥7 ng/L 95.5 (92.7-97.5) 86.7 (79.7-91.6) 23.2 (19.5-26.9) 11.3 (8.6-14.2) 
≥8 ng/L 96.1 (93.5-97.9) 87.6 (80.4-92.5) 21.6 (17.8-25.3) 11.3 (8.6-14.2) 
≥9 ng/L 96.1 (93.5-97.9) 87.0 (79.4-92.1) 20.5 (16.9-23.9) 11.3 (8.6-14.2) 
≥120 ng/L OR 
≥5 ng/L 94.1 (91.0-96.3) 87.5 (84.6-90.0) 25.9 (22.1-29.8) 9.0 (6.6-11.6) 
≥6 ng/L 96.1 (93.5-97.9) 88.7 (82.0-93.1) 23.6 (19.8-27.5) 9.0 (6.6-11.6) 
≥7 ng/L 96.1 (93.5-97.9) 88.1 (81.0-92.7) 22.4 (18.7-26.1) 9.0 (6.6-11.6) 
≥8 ng/L 97.0 (94.6-98.6) 89.9 (82.7-94.3) 20.3 (16.7-23.9) 9.0 (6.6-11.6) 
≥9 ng/L 97.0 (94.6-98.6) 89.4 (81.8-94.0) 19.3 (15.8-22.7) 9.0 (6.6-11.6) 
n.a. = not applicable. Bold printed cutoff criteria indicate the official ESC cutoff criteria combination for rule-out and rule-in; 
italic printed cutoff criteria indicate the alternative, modified cutoff criteria combination for patients with renal dysfunction.  
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Supplemental Table 14: Diagnostic performance of multiple cutoff criteria combinations using high-sensitivity cardiac troponin I 
(based on 0-hour sample concentration and 1-hour change) for rapid rule-out and rule-in of Non-ST-Segment-Elevation 
Myocardial Infarction in patients with renal dysfunction. 
 Criteria Diagnostic Performance 
 Direct Rule-
out based 
on 0h-
sample OR 
Rule-out based on 0h- and 
1h- sample Rule-out 
Sensitivity 
(95% CI) 
Rule-out NPV 
(95% CI) 
Proportion Rule-
out (95% CI) 
Proportion direct 
Rule-out based on 
0h-sample only 
(95% CI) 
0h hs-cTnI 
0h  
hs-cTnI 
AND 
1h-
change 
hs-cTnI 
R
u
le
-o
u
t 
s
tr
a
te
g
y
 
<2 ng/L OR 
<5 ng/L 
AND 
<2 ng/L 98.6 (95.0-99.8) 97.4 (90.5-99.4) 17.5 (13.9-21.4) 1.3 (0.4-2.5) 
<3 ng/L 98.6 (95.0-99.8) 97.5 (90.8-99.4) 18.2 (14.5-22.1) 1.3 (0.4-2.5) 
<6 ng/L 
<2 ng/L 98.6 (95.0-99.8) 97.9 (92.2-99.5) 21.8 (17.9-25.8) 1.3 (0.4-2.5) 
<3 ng/L 98.6 (95.0-99.8) 98.0 (92.5-99.5) 22.7 (18.8-26.7) 1.3 (0.4-2.5) 
<7 ng/L 
<2 ng/L 97.2 (93.0-99.2) 96.4 (91.0-98.6) 25.2 (21.2-29.4) 1.3 (0.4-2.5) 
<3 ng/L 97.2 (93.0-99.2) 96.7 (91.6-98.7) 27.0 (22.6-31.3) 1.3 (0.4-2.5) 
<8 ng/L 
<2 ng/L 96.5 (92.0-98.9) 96.0 (91.0-98.3) 28.3 (24.1-32.6) 1.3 (0.4-2.5) 
<3 ng/L 96.5 (92.0-98.9) 96.4 (91.8-98.5) 31.0 (26.4-35.2) 1.3 (0.4-2.5) 
<3 ng/L OR 
<5 ng/L 
AND 
<2 ng/L 98.6 (95.0-99.8) 97.4 (90.5-99.4) 17.5 (13.9-21.4) 3.4 (1.8-5.2) 
<3 ng/L 98.6 (95.0-99.8) 97.5 (90.8-99.4) 18.2 (14.5-22.1) 3.4 (1.8-5.2) 
<6 ng/L 
<2 ng/L 98.6 (95.0-99.8) 97.9 (92.2-99.5) 21.8 (17.9-25.8) 3.4 (1.8-5.2) 
<3 ng/L 98.6 (95.0-99.8) 98.0 (92.5-99.5) 22.7 (18.8-26.7) 3.4 (1.8-5.2) 
<7 ng/L 
<2 ng/L 97.2 (93.0-99.2) 96.4 (91.0-98.6) 25.2 (21.2-29.4) 3.4 (1.8-5.2) 
<3 ng/L 97.2 (93.0-99.2) 96.7 (91.6-98.7) 27.0 (22.6-31.3) 3.4 (1.8-5.2) 
<8 ng/L 
<2 ng/L 96.5 (92.0-98.9) 96.0 (91.0-98.3) 28.3 (24.1-32.6) 3.4 (1.8-5.2) 
<3 ng/L 96.5 (92.0-98.9) 96.4 (91.8-98.5) 31.0 (26.4-35.2) 3.4 (1.8-5.2) 
<4 ng/L OR 
<5 ng/L 
AND 
<2 ng/L 98.6 (95.0-99.8) 97.5 (90.7-99.4) 18.0 (14.4-21.8) 7.6 (5.3-10.2) 
<3 ng/L 98.6 (95.0-99.8) 97.6 (90.9-99.4) 18.4 (14.7-22.2) 7.6 (5.3-10.2) 
<6 ng/L 
<2 ng/L 98.6 (95.0-99.8) 98.0 (92.4-99.5) 22.2 (18.3-26.2) 7.6 (5.3-10.2) 
<3 ng/L 98.6 (95.0-99.8) 98.0 (92.6-99.5) 22.9 (19.0-26.9) 7.6 (5.3-10.2) 
<7 ng/L 
<2 ng/L 97.2 (93.0-99.2) 96.5 (91.2-98.7) 25.6 (21.5-29.9) 7.6 (5.3-10.2) 
<3 ng/L 97.2 (93.0-99.2) 96.7 (91.7-98.7) 27.2 (22.8-31.5) 7.6 (5.3-10.2) 
<8 ng/L 
<2 ng/L 96.4 (91.9-98.8) 96.1 (91.1-98.3) 28.8 (24.5-33.0) 7.6 (5.3-10.2) 
<3 ng/L 96.5 (92.0-98.9) 96.4 (91.8-98.5) 31.2 (26.7-35.3) 7.6 (5.3-10.2) 
<5 ng/L OR 
<6 ng/L 
AND 
<2 ng/L 97.9 (94.0-99.6) 97.0 (91.3-99.0) 22.7 (18.9-26.7) 11.5 (8.5-14.6) 
<3 ng/L 97.9 (94.0-99.6) 97.1 (91.5-99.0) 23.1 (19.1-27.1) 11.5 (8.5-14.6) 
<7 ng/L 
<2 ng/L 96.5 (92.0-98.9) 95.7 (90.3-98.2) 26.1 (22.0-30.2) 11.5 (8.5-14.6) 
<3 ng/L 96.5 (92.0-98.9) 95.9 (90.7-98.3) 27.4 (23.1-31.7) 11.5 (8.5-14.6) 
<8 ng/L 
<2 ng/L 95.8 (91.1-98.4) 95.4 (90.3-97.9) 29.2 (24.9-33.5) 11.5 (8.5-14.6) 
<3 ng/L 95.8 (91.1-98.4) 95.7 (91.0-98.0) 31.5 (26.9-35.7) 11.5 (8.5-14.6) 
<6 ng/L OR 
<7 ng/L 
<2 ng/L 96.5 (92.0-98.9) 95.7 (90.3-98.2) 26.3 (22.3-30.5) 14.2 (11-17.4) 
<3 ng/L 96.5 (92.0-98.9) 95.9 (90.8-98.3) 27.6 (23.3-32.0) 14.2 (11-17.4) 
<8 ng/L 
<2 ng/L 95.8 (91.1-98.4) 95.4 (90.4-97.9) 29.4 (25.1-33.8) 14.2 (11-17.4) 
<3 ng/L 95.8 (91.1-98.4) 95.7 (91.1-98.0) 31.7 (27.2-35.9) 14.2 (11-17.4) 
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Supplemental Table 14 (continued): Diagnostic performance of multiple cutoff criteria combinations using high-sensitivity 
cardiac troponin I (based on 0-hour sample concentration and 1-hour change) for rapid rule-out and rule-in of Non-ST-
Segment-Elevation Myocardial Infarction in patients with renal dysfunction. 
 Criteria Diagnostic Performance 
 Direct Rule-in 
based on 0h-
sample OR 
Rule-in 
based on 
1h-change 
Rule-in Specificity  
(95% CI) 
Rule-in PPV 
(95% CI) 
Proportion Rule-in 
(95% CI) 
Proportion direct 
Rule-in based on 
0h-sample only 
(95% CI) 0h hs-cTnI 
1h-change 
hs-cTnI 
R
u
le
-i
n
 s
tr
a
te
g
y
 
≥52 ng/L OR 
≥6 ng/L 84.4 (79.9-88.3) 70.8 (64.8-76.2) 36.2 (31.6-40.8) 27.0 (23.1-30.9) 
≥7 ng/L 86.4 (82.0-90.1) 73.6 (67.4-78.9) 34.8 (30.1-39.4) 27.0 (23.1-30.9) 
≥8 ng/L 87.1 (82.8-90.7) 74.3 (68.1-79.7) 34.2 (29.6-38.6) 27.0 (23.1-30.9) 
≥9 ng/L 87.4 (83.1-90.9) 74.5 (68.2-79.9) 33.5 (29.0-38.1) 27.0 (23.1-30.9) 
≥10 ng/L 87.4 (83.1-90.9) 74.2 (67.8-79.7) 33.0 (28.5-37.7) 27.0 (23.1-30.9) 
≥80 ng/L OR 
≥6 ng/L 85.4 (80.9-89.2) 71.6 (65.4-77.1) 34.8 (30.3-39.5) 22.0 (18.5-26.0) 
≥7 ng/L 87.4 (83.1-90.9) 74.5 (68.2-79.9) 33.5 (28.9-38.1) 22.0 (18.5-26.0) 
≥8 ng/L 88.1 (83.9-91.5) 75.3 (68.9-80.8) 32.8 (28.3-37.3) 22.0 (18.5-26.0) 
≥9 ng/L 88.4 (84.3-91.8) 75.5 (69.0-81.0) 32.1 (27.6-36.8) 22.0 (18.5-26.0) 
≥10 ng/L 88.4 (84.3-91.8) 75.2 (68.6-80.8) 31.7 (27.1-36.1) 22.0 (18.5-26.0) 
≥100 ng/L OR 
≥6 ng/L 86.1 (81.7-89.8) 72.4 (66.1-77.9) 34.2 (29.5-38.7) 20.0 (16.5-23.9) 
≥7 ng/L 88.1 (83.9-91.5) 75.3 (68.9-80.8) 32.8 (28.3-37.2) 20.0 (16.5-23.9) 
≥8 ng/L 89.1 (85.0-92.4) 76.8 (70.3-82.2) 31.9 (27.4-36.5) 20.0 (16.5-23.9) 
≥9 ng/L 89.4 (85.4-92.6) 77.0 (70.4-82.5) 31.2 (26.8-35.7) 20.0 (16.5-23.9) 
≥10 ng/L 89.4 (65.4-80.5) 76.6 (70.0-82.2) 30.8 (26.4-35.2) 20.0 (16.5-23.9) 
≥160 ng/L OR 
≥6 ng/L 86.4 (82.0-90.1) 72.5 (66.1-78.0) 33.5 (28.8-38.0) 14.4 (11.3-17.8) 
≥7 ng/L 88.7 (84.6-92.1) 75.9 (69.3-81.4) 31.7 (27.2-36.3) 14.4 (11.3-17.8) 
≥8 ng/L 89.7 (85.8-92.9) 77.4 (70.7-82.9) 30.8 (26.3-35.3) 14.4 (11.3-17.8) 
≥9 ng/L 90.1 (86.1-93.2) 77.6 (70.9-83.2) 30.1 (25.8-34.5) 14.4 (11.3-17.8) 
≥10 ng/L 90.1 (86.1-93.2) 77.3 (70.5-82.9) 29.7 (25.3-34.0) 14.4 (11.3-17.8) 
≥320 ng/L OR 
≥6 ng/L 86.8 (82.4-90.4) 73.0 (66.6-78.5) 33.0 (28.8-37.9) 10.6 (7.8-13.6) 
≥7 ng/L 89.4 (85.4-92.6) 77.0 (70.4-82.5) 31.2 (26.7-35.7) 10.6 (7.8-13.6) 
≥8 ng/L 90.4 (86.5-93.5) 78.4 (71.6-83.8) 30.1 (25.8-34.5) 10.6 (7.8-13.6) 
≥9 ng/L 90.7 (86.9-93.8) 78.5 (71.6-84.0) 29.2 (24.8-33.6) 10.6 (7.8-13.6) 
≥10 ng/L 90.7 (86.9-93.8) 78.1 (71.2-83.8) 28.8 (24.3-33.3) 10.6 (7.8-13.6) 
n.a. = not applicable. Bold printed cutoff criteria indicate the official ESC cutoff criteria combination for rule-out and 
rule-in; italic printed cutoff criteria indicate the alternative, modified cutoff criteria combination for patients with renal 
dysfunction.  
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Supplemental Table 15: Performance of the official European Society of Cardiology 
and a modified 0/1h-algorithm in patients with renal dysfunction 
Using high-sensitivity cardiac troponin T – n=487 
 
Official ESC 
0/1h-algorithm 
Modified  
0/1h-algorithm 
 
Change 
p-
value* 
Sensitivity of rule-out 100.0 (97.6-100.0) 100.0 (97.6-100.0) ±0% 1.0 
NPV of rule-out 100.0 (n.a.) 100.0 (n.a.) ±0% 1.0 
Specificity of rule-in 88.7 (84.8-91.9) 92.6 (89.2-95.1) +3.9%  <0.001 
PPV of rule-in 76.5 (70.6-81.6) 81.5 (74.9-86.7) +5.0% 0.001 
Proportion ruled-out 18.1 (14.6-21.6) 22.6 (18.8-26.7) +4.5% <0.001 
  - based on 0h-sample only 1.4 (0.4-2.6) 1.6 (0.6-2.9) +0.2% 1.0 
  - based on 0h/1h-samples 16.6 (13.5-20.0) 21.0 (17.2-24.5) +4.4% <0.001 
Proportion ruled-in 33.3 (29.3-37.5) 27.7 (23.7-31.7) -5.6% <0.001 
  - based on 0h-sample 25.9 (22.4-29.7) 15.2 (11.9-18.4) -10.7% <0.001 
  - based on 1h-sample 7.4 (5.2-9.6) 12.5 (9.7-15.6) +5.1% 0.008 
Overall Efficacy 51.3 (46.8-55.8) 50.3 (45.9-55.2) -1.0% 0.568 
Prevalence of NSTEMI in the 
observational group 
11 (7-15) 17 (12-22) +6% 0.010 
Using high-sensitivity cardiac troponin I – n=445 
 
Official ESC 
0/1h-algorithm 
Modified  
0/1h-algorithm 
 
Change 
p-
value* 
Sensitivity of rule-out 98.6 (95.0-99.8) 98.6 (95.0-99.8) ±0% 1.0 
NPV of rule-out 97.4 (90.5-99.4) 98.0 (92.4-99.5) +0.6% 0.177 
Specificity of rule-in 84.4 (79.9-88.3) 88.1 (83.9-91.5) +3.7% 0.001 
PPV of rule-in 70.8 (64.8-76.2) 75.3 (68.9-80.8) +4.5% 0.004 
Proportion ruled-out 17.5 (13.9-21.4) 22.2 (18.3-26.2) +4.7% <0.001 
  - based on 0h-sample only 1.3 (0.4-2.5) 7.6 (5.3-10.2) +6.3% <0.001 
  - based on 0h/1h-samples 16.2 (12.7-19.7) 14.6 (11.4-18.2) -1.6% 0.371 
Proportion ruled-in 36.2 (31.6-40.8) 32.8 (28.3-37.2) -3.4% <0.001 
  - based on 0h-sample 27.0 (23.1-30.9) 20.0 (16.5-23.9) -7.0% <0.001 
  - based on 1h-sample 9.2 (6.5-12.0) 12.8 (9.7-16.1) +3.6% 0.004 
Overall Efficacy 53.5 (49.2-58.0) 54.6 (49.8-59.1) +1.1% 0.500 
Prevalence of NSTEMI in the 
observational group 
13 (9-18) 15 (11-20) +2% 0.390 
 
Numbers represent percentage (95% confidence interval). * performances measures of the 
official and the modified 0/1h-algorithms were compared using McNemar test or the 
method described by Moskowitz et al.16 Bold printed p-values indicate statistical 
significance. n.a. = not applicable; NPV = negative predictive value; NSTEMI = Non-ST-
Segment-Elevation Myocardial Infarction, PPV = positive predictive value.  
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Supplemental Figures 
 
 
(A) general concept of the European Society of Cardiology 0/1h-algorithm 
(B) assay-specific cutoff values for Elecsys high-sensitivity cardiac troponin T 
(C) assay-specific cutoff values for Architect high-sensitivity cardiac troponin I 
  
Supplemental 
Figure 1 
0/1h-algorithm of the European Society of Cardiology to rapidly 
rule-out and rule-in Non-ST-Segment-Elevation Myocardial 
Infarction  
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Supplemental 
Figure 2 
Patient flow diagramm 
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Correlations between renal function expressed by the estimated glomerular filtration rate 
and: 
(A) concentrations of high-sensitivity cardiac troponin T at presentation. 
(B) concentrations of high-sensitivity cardiac troponin I at presentation. 
(C) absolute 1-hour changes of high-sensitivity cardiac troponin T. 
(D) absolute 1-hour changes of high-sensitivity cardiac troponin I. 
 
among patients with acute myocardial infarction (red dots) and without acute myocardial 
infarction (blue dots). NSTEMI = Non-ST-Segment-Elevation Myocardial Infarction; GFR = 
glomerular filtration rate. 
 
Supplemental 
Figure 3 
Correlations between glomerular filtration rate and concentrations at 
presentation and absolute 1-hour changes in high-sensitivity cardiac 
troponin 
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Receiver-operating characteristic (ROC) curves describing the discriminative performance 
to identify Non-ST-Segment-Elevation Myocardial Infarction  in patients with normal renal 
function (green line) and renal dysfunction (red line) using: 
(A) concentrations of high-sensitivity cardiac troponin T at presentation. 
(B) concentrations of high-sensitivity cardiac troponin I at presentation. 
(C) absolute 1-hour changes of high-sensitivity cardiac troponin T. 
(D) absolute 1-hour changes of high-sensitivity cardiac troponin I. 
 
AUC = Area under the receiver operating characteristic curve with its corresponding 95% 
confidence interval. P-value for comparison of independent AUC-curves. 
 
Supplemental 
Figure 4 
Diagnostic performance of high-sensitivity cardiac troponin in 
patients with renal dysfunction and normal renal function. 
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Flow-charts depicting the diagnostic performance of  
(A) the official European Society of Cardiology 0/1h-algorithm and  
(B) an alternative, modified 0/1h-algorithm  
for rule-out and rule-in Non-ST-Segment-Elevation Myocardial Infarction among patients 
presenting with suspected myocardial infarction and with renal dysfunction using high-sensitivity 
cardiac troponin T (hs-cTnT, Elecsys). NSTEMI = non-ST-segment elevation myocardial infarction; 
1h-change= absolute (unsigned) change of high-sensitivity cardiac troponin T within 1 hour; NPV = 
negative predictive value; PPV = positive predictive value; n.a. = not applicable. *if chest pain 
onset > 3 hours before presentation to the emergency department. Green colored curls highlight 
modified cutoff criteria compared to the official ESC 0/1h-algorithm; ▲ indicates a significant 
increase of the respective diagnostic parameter using the modified 0/1h-algorithm as compared to 
the official ESC 0/1h-algorithm, ▼ indicates a significant decrease of the respective diagnostic 
parameter using the modified 0/1h-algorithm as compared to the official ESC 0/1h-algorithm, = 
indicates no significant change between the two algorithms. Green colored arrows indicate 
favorable change, red colored arrows indicate unfavorable change using the modified 0/1h-
algorithm as compared to the original 0/1h-algorithm. 
Supplemental 
Figure 5 
Performance of the official ESC and an alternative, modified 0/1h-algorithm 
using high-sensitivity cardiac troponin T in patients with renal dysfunction. 
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Flow-charts depicting the diagnostic performance of  
(A) the official European Society of Cardiology 0/1h-algorithm and  
(B) an alternative, modified 0/1h-algorithm  
for rule-out and rule-in Non-ST-Segment-Elevation Myocardial Infarction among patients 
presenting with suspected myocardial infarction and with renal dysfunction using high-sensitivity 
cardiac troponin I (hs-cTnI, Architect). NSTEMI = non-ST-segment elevation myocardial infarction; 
1h-change= absolute (unsigned) change of high-sensitivity cardiac troponin I within 1 hour; NPV = 
negative predictive value; PPV = positive predictive value; n.a. = not applicable. *if chest pain 
onset > 3 hours before presentation to the emergency department. Green colored curls highlight 
modified cutoff criteria compared to the official ESC 0/1h-algorithm; ▲ indicates a significant 
increase of the respective diagnostic parameter using the modified 0/1h-algorithm as compared to 
the official ESC 0/1h-algorithm, ▼ indicates a significant decrease of the respective diagnostic 
parameter using the modified 0/1h-algorithm as compared to the official ESC 0/1h-algorithm, = 
indicates no significant change between the two algorithms. Green colored arrows indicate 
favorable change, red colored arrows indicate unfavorable change using the modified 0/1h-
algorithm as compared to the original 0/1h-algorithm. 
Supplemental 
Figure 6 
Performance of the official ESC and an alternative, modified 0/1h-algorithm 
using high-sensitivity cardiac troponin I in patients with renal dysfunction. 
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Kaplan-Meier curves depicting major adverse cardiac events (MACE)-free survival within 30 days 
for patients with normal renal function (dashed lines) and renal dysfunction (full lines) stratified by 
the European Society of Cardiology 0/1h-algorithm to the rule-out (green lines), observational 
(orange lines) and rule-in (red lines) group 
(A) using high-sensitivity cardiac troponin T (left panel) 
(B) using high-sensitivity cardiac troponin I (right panel). 
MACE = major adverse cardiac events, defined as the composite of all-cause mortality, myocardial 
infarction (including index event), cardiogenic shock, ventricular tachyarrhythmias, or higher-
degree atrioventricular block. 
  
Supplemental 
Figure 7 
MACE-free survival according to risk stratification group by the European 
Society of Cardiology 0/1h-algorithm using high-sensitivity cardiac troponin 
T and I in patients with normal renal function and renal dysfunction. 
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